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Testosterone products are recommended by some prescribers in response to a diagnosis
or presumption of “low testosterone” (low-T) for cardiovascular health, sexual function,
muscle weakness or wasting, mood and behavior, and cognition. We performed a systematic review of 156 eligible randomized controlled trials in which testosterone was compared
to placebo for one or more of these conditions. We included studies in bibliographic databases between January 1, 1950 and April 9, 2016, and excluded studies involving bodybuilding, contraceptive effectiveness, or treatment of any condition in women or children.
Studies with multiple relevant endpoints were included in all relevant tables. Testosterone
supplementation did not show consistent benefit for cardiovascular risk, sexual function,
mood and behavior, or cognition. Studies that examined clinical cardiovascular endpoints
have not favored testosterone therapy over placebo. Testosterone is ineffective in treating
erectile dysfunction and controlled trials did not show a consistent effect on libido. Testosterone supplementation consistently increased muscle strength but did not have beneficial
effects on physical function. Most studies on mood-related endpoints found no beneficial
effect of testosterone treatment on personality, psychological well-being, or mood. The prescription of testosterone supplementation for low-T for cardiovascular health, sexual function, physical function, mood, or cognitive function is without support from randomized
clinical trials.

Data Availability Statement: This is a systematic
review. Studies we reference are available in the
public domain.
Funding: There were no funding sources for this
study. Dr. Scialli is the sole participant in Scialli
Consulting LLC. Scialli Consulting LLC has no
employees and did not support this study with
either salary or any other funding. Scialli Consulting
LLC did not have any role in the study design, data
collection and analysis, decision to publish, or
preparation of the manuscript. The specific role of
this author is articulated in the ‘author
contributions’ section.

1. Introduction
Testosterone and methyltestosterone are marketed in the United States for men with congenital or acquired hypogonadism. Some practitioners have used testosterone preparations to treat
a variety of symptoms identified as those of “low testosterone” (low-T), a term that has not
been uniformly defined. We present a systematic review of randomized controlled trials
(RCTs) that evaluated the use of testosterone therapy against placebo or inactive comparator in
adult men for cardiovascular health, sexual function, muscle weakness/wasting, mood and
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behavior, or cognition. We did not include studies of testosterone in men with missing or damaged testicles, or who had Klinefelter syndrome or other genetic anomalies. We did not include
studies on the use of testosterone for any indication in women or in children, the use of androgens in contraception, or the use of androgens for bodybuilding or athletic performance.

2. Methods
2.1 Data Search, Synthesis and Analysis
Computerized literature searches were conducted in PubMed, Embase, and APA PsycNET.
Searches were limited to human males but were not restricted by language or date. The
PubMed search was conducted using the MeSH term “testosterone” and the modifiers “administration and dosage,” “adverse effects,” “deficiency,” “standards,” “therapeutic use,” or “therapy.” The original PubMed search was conducted for studies published between January 1,
1950 and November 26, 2013. The Embase search was conducted using the Emtree key term
“testosterone,” modified by “adverse drug reaction,” “androgen deficiency,” “therapy,” “drug
dose,” or “clinical trial.” The original Embase search was conducted for studies published
between January 1, 1974 and November 26, 2013. The PsycNET search was conducted using
the term “testosterone” modified by “addiction,” “drug dependency,” “therapy,” “treatment,”
or “deficiency.” The original PsycNET search was conducted for studies published between
January 1, 1806 and November 26, 2013. All searches were repeated on April 9, 2016 to identify
clinical trials that had been published since the initial search, so the final search included more
than four decades of trials from all databases.

2.2 Study Selection
Search results were combined using EndNote and duplicates were deleted. These results were
filtered using the key term “clinical trial.” Titles and abstracts were reviewed to identify RCTs
and eliminate irrelevant studies. Relevant studies were retrieved.

2.3 Data Extraction
Data were extracted into tables by 4 independent reviewers according to the presence of information on cardiovascular health, sexual function, muscle weakness/wasting, mood and behavior, or cognition. Studies with multiple relevant endpoints were included in all relevant tables.
Review articles were identified and retrieved, and their reference lists were searched for primary publications of RCTs.
Some studies that included randomized controlled designs also included open-label continuation phases. We evaluated and summarized the randomized controlled portions of these
studies. Although our primary interest was the use of testosterone for the treatment of hypogonadism, however defined by study authors, we included trials of testosterone in eugonadal
men. In some studies, eugonadal subjects were randomized to receive testosterone or a comparator (usually placebo), and hypogonadal subjects were treated with testosterone only. We
evaluated and summarized only the randomized portions of these studies.

2.4 Quality Assessment
We assessed quality of studies by a 5-point Jadad score. In order to be as inclusive as possible,
we included all studies identified regardless of Jadad score. For clinical endpoints only (angina/
ischemia, congestive heart failure, and erectile dysfunction) we also included an analysis of
studies restricted to Jadad scores of 4 or 5. We accepted whatever criteria were used by individual study authors to define low testosterone.
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3. Results
Fig 1 lists the exclusion criteria used to select 226 qualifying papers from 11,417 reviewed
abstracts. Although most studies were described by their authors as randomized, not all indicated
the nature of the randomization procedures. Some studies included identical numbers of subjects
in treatment and exposed conditions, suggesting that allocation was not random. After further
examination, 70 papers did not meet our criteria, so the final data set included 156 papers.

Fig 1. Literature Search and Study Selection.
doi:10.1371/journal.pone.0162480.g001
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3.1 Cardiovascular Health
Table 1 summarizes extracted studies that focused on the effect of testosterone on cardiovascular endpoints, including 17 studies on ischemia/angina, 6 on congestive heart failure (CHF), 25
on lipids, and 11 on inflammatory and coagulation markers.
3.1.1 Coronary artery disease. In studies that investigated the effect of testosterone on
patients with coronary artery disease (CAD), eligible men generally were identified based on
stable angina, angiographic evidence of some degree of coronary artery occlusion, or a history
of myocardial infarction (MI). Six studies involved men in whom the study authors reported
evidence of hypogonadism either clinically [1] or based on plasma testosterone concentration
[2–6]; the remainder included men without regard to plasma testosterone concentration. All
but three of the studies evaluated ST-segment depression on an exercise stress test using a
modification of the Bruce protocol. One of the studies not using the Bruce protocol evaluated
findings on electrocardiography (ECG) and Holter monitoring, without specification of an
exercise protocol.[7] Another study added single-photon emission computer tomography
(SPECT) to evaluate for deficits in myocardial uptake of a labeled perfusion tracer.[8] One
study used magnetic resonance imaging (MRI) estimates of myocardial perfusion.[3] One
study evaluated change in coronary artery calcium score over time, showing no difference
between testosterone and placebo.[6]
Two studies evaluated brachial artery response to release of occlusion as an indicator of sensitivity to local vasodilators in men with CAD and did not directly address the coronary arteries; both reported results favorable to testosterone therapy.[9, 10] Two studies in apparently
healthy men with bioavailable testosterone <4.44 nM (128 ng/dL) or total testosterone 15
nM (432 ng/dL) found no change in brachial artery reactivity in response to transdermal testosterone or dihydrotestosterone therapy.[5, 11] The study that used MRI showed no effect of
8 weeks of oral testosterone undecanoate therapy on myocardial perfusion, although there was
increased perfusion of those segments supplied by an unobstructed coronary artery.[3]
Three studies used acute treatments with intravenous (IV) testosterone just prior to exercise
testing. Two of the studies showed favorable effects of treatment on time to ST-segment
depression.[2, 12] One study showed no effect on ECG or SPECT evidence of ischemia.[8] A
year-long study showed benefits of testosterone treatment on ST-segment depression.[4] The
remaining eight studies evaluated treatments of 2 to 24 weeks in duration.[1, 3, 10, 11, 13–17]
The 3 studies that looked at time to ST-segment depression found a benefit of testosterone supplementation.[1, 14, 16]
Although 2 studies reported improvements in angina symptoms during or after testosterone
treatment,[7, 15] 4 studies showed no effect of treatment on angina.[1, 4, 8, 16] Most studies
did not report any measure of angina symptoms. A study on men with leg claudication or trophic ulcers attributed to arteriosclerosis did not show an improvement in subjective symptoms,
walking, or plethysmographic estimation of blood flow endpoints after 3 months of testosterone therapy.[13]
There was a decreased incidence of silent MI with testosterone treatment in 1 study.[15]
Another study, designed to determine the effect of testosterone supplementation on lowerextremity strength and physical function in men 65 years of age and older, was stopped early
by a Data and Safety Monitoring Board due to an excess of cardiovascular adverse events.[17]
These adverse events included acute coronary syndrome (ACS), MI, ECG abnormalities, and
arrhythmias, among others.
Eleven studies of coronary artery disease scored 4 or 5 on the Jadad scale. Of these, only one
of five studies that included angina as an outcome found a benefit. Four of five studies that
assessed ST segment depression found a benefit.
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Table 1. Effects of Testosterone on Cardiovascular Endpoints.
ISCHEMIA/ANGINA
Acute Intravenous Treatment
Rosano et al, 1999
[12]

14 men 45–66 years old with coronary
artery disease (CAD).

2.5 mg testosterone (T) or intravenous
(IV) placebo over 5 min, 30 min prior to
exercise test; tx switch at 2 days;
randomization by computer; masking not
described.

"Time to ST segment depression.
3
#Maximum ST segment depression. #ST
recovery.

Ong et al, 2000[9]

22 men with CAD.

2.3 mg T or placebo IV over 10 min
(n = 11) with switch after 1 week; 0.023–
0.046 mg T or placebo IV over 10 min
(n = 11) with tx switch after 1 week;
randomization method not given.

"Percent change in brachial artery
diameter after release of occlusion with
high-dose T. No change in flow velocity
in brachial artery after release of
occlusion. Low-dose T had no effect.
Interpreted as enhanced response to
local effects of nitric oxide after T.

3

Thompson et al,
2002[8]

34 men 69 ± 6 years old (mean ± SD) with T or placebo by bolus IV over 20 min with
CAD and exercise- or adenosinemaintenance IV to increase basal serum T
inducible ischemia.
concentration 0, 2-, or 6-fold with each
subject receiving all 3 conditions randomly
1 week apart; randomization method not
given.

No effect on time to ST segment
depression or myocardial perfusion
defects by SPECT. No effect on time to
angina in the 5 subjects who
experienced angina during testing.

4

Webb et al, 1999[2] 14 men 35–75 years old with CAD and
plasma T concentration  11 nM (317 ng/
dL).

2.3 mg T or placebo IV over 10 min 30 min "Time to ST segment depression. No
prior to exercise test; 1 week later under tx change in maximum ST segment
switch; randomization method not given.
depression or in time to onset of angina.

4

300 mg aqueous T isobutyrate or placebo
(meprobamate) every 14 days for 3
months; route of administration not given;
double-blind; randomization method not
given.

No effect on subject improvement,
walking test, plethysmographic
estimation of pulse volume, blood flow at
rest or after exercise, or hyperemia after
compression. "Skin temperature.

3

2–24 Week Treatment Period
Dohn et al, 1968
[13]

44 men with leg claudication or ulcers
attributed to arteriosclerosis (n = 43) or
Buerger’s diseas (n = 1). Two men did not
complete study, but numbers in tables
add to 86 subjects. Not possible to tell for
sure how many men were analyzed.

Ly et al, 2001[11]

37 men mean age 68.2 years with plasma 70 mg dihydrotestosterone (DHT) gel
T concentration 15 nM (432 ng/dL); 4
(n = 18) or placebo (n = 19) applied daily
dropouts were excluded from analysis.
for 3 months; randomization method not
given.

No effect on flow- or nitroglycerinmediated dilatation of brachial artery.

5

Kang et al, 2002
[10]

35 men mean age 58 years with CAD.

160 mg testosterone undecanoate PO
daily for 4 weeks then 80 mg daily for 8
weeks (n = 18); placebo tx (n = 17) not
given; randomization method not given.

"Flow- and nitroglycerin-mediated
dilatation of brachial artery.

1

Malkin et al, 2004
[1]

12 men 60.8 ± 4.6 years old (mean ± SD)
with CAD and “clinical need for T
replacement.” One man failed screening
and another withdrew at unspecified point
in the study.

100 mg T or placebo IM every 2 weeks for "Time to ST segment depression. No
4 weeks, 1 month washout, then tx switch; significant change in Seattle Angina
randomization by computer; single-blind.
Score. #Beck Depression Inventory
(BDI) score.

Jaffe, 1977[14]

50 men 35–71 years old with postexercise ST segment depression.

200 mg T cypionate (n = 25) or placebo IM #Sum of ST segment depression in leads 4
(n = 25) weekly for 8 weeks,
II, V4, 5, and 6 at 0, 2, 4, and 6 min after
randomization method not given.
exercise. Symptoms not evaluated.
Described as double-blinded.

Cornoldi et al,
2009[15]

87 men 57–74 years old with chronic
angina, CAD, or prior myocardial
infarction (MI).

40 mg T undecanoate (n = 43) or placebo
(n = 44) PO TID for 12 weeks; doubleblind; randomization by computer.

#Incidence of silent myocardial
infarction. #Total ischemic burden.
#Number of anginal attacks/week.

5

English et al, 2000
[16]

50 men mean age 62 years with stable
CAD.

5 mg daily T patch (n = 25) or placebo
(n = 25) for 12 weeks; double-blind;
randomization method not given. Three
withdrawals from T arm and 1 withdrawal
from placebo arm eliminated from
analysis.

"Time to ST-segment depression by
week 14. No change in angina
frequency. Improved quality of life (QoL)
scores.

4

5

(Continued)
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Table 1. (Continued)
Webb et al, 2008[3] 25 men 40–75 years old with
angiographically proven CAD (70%
lesion in at least one major coronary
artery or major branch), plasma T
concentration 12 nM (346 ng/dL); 2
dropouts prior to medication tx were not
analyzed. One subject had unanalyzable
data.

160 mg/day T undecanoate or placebo
PO for 8 weeks followed by tx switch.
Method of randomization not given.

No change in global myocardial
perfusion by magnetic resonance
imaging (MRI). "Perfusion of segments
supplied by coronary arteries without
significant obstruction. "Left ventricular
(LV) ejection fraction (EF) (by 2%). No
change in stroke volume (SV), endsystolic volume (ESV), end-diastolic
volume (EDV), or heart mass.

4

Basaria et al, 2010
[17]

209 men 65 years old with total serum T
100–350 ng/dL (3.5–12.1 nM) or free
serum T <50 pg/mL (174 pM) and with
mobility limitations. Analysis restricted to
176 men with a baseline assessment and
at least one outcome assessment.

100 mg T (n = 106) or placebo (n = 103)
gel daily for 6 months. After 2 weeks, dose
level was increased or decreased by 50%
based on serum T. Randomization was by
age blocks but was not otherwise
described.

"Cardiovascular-related adverse events
(AEs), adjusted OR 5.8, 95% CI 2.0–
16.8 (includes acute coronary syndrome
[ACS]–chest pain, syncope, MI, stroke,
congestive heart failure [CHF]
exacerbation, coronary stenting and
bypass procedures, peripheral edema,
elevated blood pressure [BP],
arrhythmias, ECG changes).

5

Wu et al, 1993[7]

62 men 55–75 years old with angina.

120 mg T undecanoate PO QD × 2 weeks #Ischemia on ECG and Holter recordings 2
then 40 mg/day × 2 weeks or placebo for 2 by subjective scoring system. #Angina
weeks followed by 2-week washout, then by subjective scoring system.
tx switch; described as randomized, but
there were 31 men in each group and
randomization was not described.

12-Month Treatment Period
Mathur et al, 2009
[4]

15 men 64.8 ± 7 years old (mean ± SD)
with stable chronic angina, ST segment
depression at baseline, and at least 2
early morning serum T
concentrations < 12 nM (346 ng/dL); one
man assigned to each arm withdrew at
unspecified point in the study.

1000 mg T undecanoate depot IM (n = 6)
or placebo (n = 7) q 3 months × 12
months; randomized by computer;
described as double-blind.

"Time to ST segment depression at 14,
28, and 52 weeks and increased level of
exercise attained. No significant change
in Seattle Angina Score (SAS).

4

Kenny et al, 2002
[5]

67 men 65–87 years old (mean 74) with
bioavailable T <4.44 nM (128 ng/dL); 23
dropouts (10 T, 13 placebo) and 8 men
with technical difficulties were not
included in the analysis.

5 mg daily T patch (n = 34) or placebo
(n = 33) × 12 months. Randomization
method not described.

No change in vascular reactivity after
occlusion.

3

Basaria et al, 2015
[6]

Men aged 60 years or older, morning total
T 100–400 ng/dL (3.5–14 nM) or free <50
testosterone pg/mL (1.7 pM). 1:1
concealed randomization with
stratification by age dichotomized at 75
years and by site. Computer-generated
randomization. All subjects receiving at
least 1 medication dose were retained for
analysis.

3 years of daily application of 75 (n = 155)
or 0 (n = 151) mg testosterone as a gel,
dose level adjusted upwards or
downwards based on total testosterone
2–12 hours after gel application. Placebo
adjusted by an unblinded observer. 44/
155 receiving T did not complete, 23 for
adverse events; 51/151 receiving placebo
did not complete, 17 for adverse events.

No difference in carotid artery intimamedia thickness or in rate of thickening
over time; No difference in coronary
artery calcium score change over time

5

"Distance in 6-minute walk test. "Body
mass index (BMI). "O2 consumption.
#Ventilation/CO2 output. #Diastolic BP.
No change in EF or LV end-diastolic
diameter.[18] #QT interval (0.8%) and
#QTc interval (1.5%).[87]

4

CONGESTIVE HEART FAILURE
Caminiti et al,
70 men 66–76 years old (mean age 70)
2009[18]; Schwartz with stable CHF (NYHA II or III) and LV Ef
et al, 2011[87]
<40%. Dropouts (4 on T and 2 on
placebo) and lost data (1 on T and 5 on
placebo) were not included in analysis.

1000 mg T undecanoate (n = 35) or saline
(n = 35) IM at 6 and 12 weeks. Subjects
said to be randomized, but randomization
method was not given.

(Continued)
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Table 1. (Continued)
Pugh et al, 2003
[19]

12 men 48–82 years old with stable CHF;
8 men characterized as having ischemic
heart disease, 2 had dilated
cardiomyopathy, 1 had hypertension, and
1 had alcohol-related heart failure.

60 mg T or placebo given buccally
followed the next day by tx switch.
Described as randomized, but
randomization method not given.

Cardiac index was positively correlated
3
and systemic vascular resistance
negatively correlated with serum free T
concentration. T attenuated the fall in
cardiac index and the rise in systemic
vascular resistance associated with the
catheterization procedure. No effect of tx
on pulmonary capillary wedge pressure.
Another report of this trial found no effect
on serum concentration of TNF-α.[21]

Pugh et al, 2004
[20]

20 men 44–81 years old with impaired LV
EF (mean 35%).

100 mg T or placebo IM every 2 weeks for
12 weeks. Subjects said to be
randomized, but randomization method
and number of subjects per group not
given.

Distance walked was increased more by
T than by placebo. T improved heart
failure symptom scores compared to
baseline. There was no improvement
after placebo. There were no effects of T
on LV size, or EF.

Malkin et al, 2006
[23]

76 men with CHF, mean age ~64 years;
34 dropouts were retained for analysis
using ITT.

5 mg T (n = 37) or placebo (n = 39) patch
daily for 12 months; randomization
stratified by ischemic vs non-ischemic
heart failure. Method of randomization not
given.

15% improvement in distance on shuttle 3
walk test. More subjects on T (35%) than
placebo (8%) improved in NYHA class.

Mirdamadi et al
2014[22]

50 males, age 50–70, with CHF.

T enanthate 250 mg IM or saline placebo
IM every 4 weeks for 12 weeks.

No difference between groups in blood
3
pressure (SBP or DBP), ejection fraction,
or other cardiovascular end points
assessed by echocardiography. A
Doppler-based myocardial performance
index improved in the treatment group.

3

LIPIDS
Favorable Effects on Lipids
Uyanik et al, 1997
[155]

37 healthy men 53–89 years old.

120 mg daily T undecanoate (n = 17) or
placebo (n = 20) PO for 2 months.

#Total serum cholesterol (12%). #LDL
cholesterol (20.7%). No change in HDL
cholesterol or triglycerides.

0

Tenover, 1992
[156]

13 healthy men 57–76 years old with
serum T 13.9 nM (400 ng/dL).

100 mg T enanthate or placebo IM weekly
x 3 months followed by tx switch x 3
months; described as randomized, but
randomization procedure not described.
Six subjects received T first.

#Total serum cholesterol (11%). #LDL
cholesterol (12%). No effect on HDL
cholesterol, apolipoprotein A-1, or
triglycerides.

4

Ly et al, 2001[11]

37 men mean age 68.2 years with plasma 70 mg dihydrotestosterone (DHT) gel
#Total serum cholesterol (~10%). #LDL
T concentration 15 nM (432 ng/dL); 4
(n = 18) or placebo (n = 19) applied daily
cholesterol (~10%). No change in HDL
dropouts were excluded from analysis.
for 3 months; method of randomization not cholesterol or triglycerides.
discussed.

5

Howell et al, 2001
[24]

35 men, mean age 40.9 years after
cancer chemotherapy; serum luteinizing
hormone 8 IU/L and serum T < 20 nM
(576 ng/dL); 2 subjects did not complete
the study; it is not known if they were
included in analysis.

2.5 mg T (n = 16) or placebo (n = 19)
patch daily for 2–4 weeks then dose
increased to 2 patches daily for remainder
of 12 months unless serum T >20 nM;
randomization method not given.

#LDL cholesterol (13%) for periodic
measurements averaged over months
3–12. No change in triglycerides, LDL
cholesterol, HDL cholesterol.

3

Malkin et al, 2004
[27]

29 men 36–78 years old with a clinical
indication for T replacement for
hypogonadism; 2 subjects were
withdrawn and 2 additional patients did
not contribute analyzable sera.

100 mg T (n = 27) or placebo IM (n = 27)
#Total serum cholesterol (6%).
every 2 weeks; randomization using
#Triglycerides (11%). No effect on LDL
blocks of computer-generated numbers. A or HDL cholesterol.
crossover design appears likely, although
not explicit.

5

Malkin et al, 2004
[1]

12 men 60.8 ± 4.6 years old (mean ± SD)
with CAD and “clinical need for T
replacement”; one man failed screening,
one man withdrew at unspecified point in
the study.

100 mg T or placebo IM every 2 weeks for
4 weeks, washout for 1 month, then
opposite tx; order of tx randomized by
computer; described as single-blinded.

5

#Total serum cholesterol (6%). No effect
on LDL or HDL cholesterol or
triglycerides.

(Continued)
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Table 1. (Continued)
Kapoor et al, 2006
[157]

27 men, 52–76 years old (mean age 54
years) with type 2 diabetes mellitus
(T2DM) and total T <12 nM (346 ng/dL)
with symptoms attributed to
hypogonadism; 3 men were excluded due
to protocol violations.

200 mg sustanon (30 mg T propionate, 60
mg T phenylpropionate, 60 mg T
isocaproate, and 100 mg/mL T
decanoate) or placebo IM every 2 weeks
for 6 injections followed by a 1-month
washout period followed by tx switch;
randomization by computer-derived
random number table; number in each
arm not stated.

#Total serum cholesterol (5%). No effect
on LDL or HDL cholesterol or
triglycerides.

5

Mathur et al, 2009
[4]

15 men 64.8 ± 7 years old (mean ± SD)
with stable chronic angina, ST segment
depression at baseline, and at least 2
early morning serum T
concentrations < 12 nM (346 ng/dL); one
man assigned to each arm withdrew at
unspecified point in the study.

1000 mg T undecanoate depot IM (n = 6)
or placebo (n = 7) q 3 months for 12
months; randomized by computer;
described as double-blind.

#Triglycerides (% change not available).
No effect on total or HDL cholesterol.

4

Cornoldi et al,
2010[15]

87 men 57–74 years old with chronic
angina, CAD, or prior MI.

40 mg T undecanoate (n = 43) or placebo
(n = 44) PO TID for 12 weeks; doubleblind; randomization by computer.

#Serum total cholesterol (7%).
#Triglycerides (14%). No effect on HDL
cholesterol.

5

Gianatti et al 2014
[32]

88 men age 35–70 years of age with a
history of type 2 diabetes mellitus (T2DM)
and total testosterone 12.0 nM (346 ng/
dL). 13 men did not complete the study, 8
because of intensification of oral
hypoglycemic agents or commencement
of insulin therapy. 1 subject in
testosterone group was withdrawn with a
hematocrit of >54 prior to his 30 week
injection.

Participants were randomly assigned in a #Total cholesterol (12%); # LDL
cholesterol (13%); " HDL cholesterol
concealed 1:1 allocation to T or placebo
using permuted blocks with a block size of (9%); No change in triglycerides
4. IM T undecanoate 1000 mg (n = 45) or
placebo (n = 43) at 0, 6, 18, and 30 weeks.

Hackett et al 2014
[158]

199 Men aged 18–80 with T2D with a total Subjects were block randomized to
T 8.1–12 nM (234–346 ng/dL) or total T of receive T undecanoate IM at 0 (n = 102)
8.0 nM (231 ng/dL). 9 patients did not
or 1000 (n = 97) mg at week 0, 6, and 18.
complete the study; 4 because of serious
adverse events (3 treatment unrelated
deaths, 1 prostate cancer in placebo) and
5 withdrew their consent.

4

#Total cholesterol (6%); No change in
LDL or HDL cholesterol or triglycerides

5

No effect on total HDL and LDL
cholesterol or on triglyceride serum
concentration.

1

Lack of Favorable Effects on Lipids
Kang et al, 2002
[10]

35 men mean age 58 years with CAD.

160 mg T undecanoate PO daily for 4
weeks then 80 mg daily for 8 weeks
(n = 18). Placebo tx (n = 17) not
described. Randomization method not
given.

Kenny et al, 2002
[5]

67 men 65–87 years old (mean 74) with
bioavailable T <4.44 nM (128 ng/dL); 23
dropouts (10 T, 13 placebo) not included
in the analysis.

5 mg daily T patch (n = 34) or placebo
#HDL (9%) and HDL2 (15%) cholesterol.
(n = 33) for 1 year. Randomization method No change in total, LDL cholesterol,
not described.
triglycerides, or lipoprotein-a (LP-a).

3

Chung et al, 2007
[61]

30 healthy men 18–45 years old.

200 mg T (n = 10), nonandrolone (n = 10), No effect on total, LDL, or HDL
or placebo IM (n = 10) weekly for 4 weeks; cholesterol or triglyceride serum
computer-generated randomization list
concentrations.
with block design.

5

Kouri et al, 1996
[159]

16 healthy men 20–43 years old.

T cypionate IM (150 mg at weeks 1 and 2
[n = 8], 300 mg at weeks 3 and 4 [n = 8],
and 600 mg at weeks 5 and 6 [n = 8]) or
placebo followed by 6-week washout
followed by opposite tx and another
6-week washout. Described as
randomized, procedure not given.

3

#HDL cholesterol (21%). No effect on
LDL cholesterol.

(Continued)
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Table 1. (Continued)
Jockenhövel et al,
1999[25]

55 men with hypogonadism (serum T
concentration <3.6 nM [105 ng/dL]);
androgen therapy withdrawn 3 months
prior to study in men using such therapy.

Randomized by unspecified method to
"Total serum cholesterol (6–20%). "LDL
mesterolone (n = 12; not further discussed cholesterol (47–65%). #HDL cholesterol
here), T undecanoate 160 mg/day PO
(33–36%). "Triglycerides (23–46%).
(n = 13), T enanthate (n = 15) 250 mg IM
every 21 days, T subcutaneous pellet 200
mg implanted once (n = 15). Open label.

1

Snyder et al, 2001
[160]

108 healthy men over 65 years old (mean
age 73 years) with serum T concentration
at least 1 standard deviation below the
mean for young men (16.5 nM [476 ng/
dL]).

6 mg daily scrotal T patch (n = 54) or
placebo (n = 54); dose could be reduced
to 4 mg daily if serum T >1000 ng/dL (34.7
nM). Study described as randomized and
double-blinded; randomization method not
discussed.

No effect on serum concentrations of
total, HDL, or LDL cholesterol,
triglycerides, apolipoprotein B,
apolipoprotein A-1, or LP-a.

4

160 mg/day T undecanoate or placebo by
mouth for 8 weeks followed by crossover
to the other tx. Allocation of tx order not
discussed.

#HDL cholesterol (9%). No change in
total or LDL cholesterol or triglycerides.

4

Agledahl et al,
2008[161]

27 men, average age 69 years and serum 1000 mg T undecanoate (n = 14) or
T <11.0 nM (317 ng/dL); 1 dropout
placebo (n = 13) IM at 0, 6, 16, 28, and 40
excluded from analysis.
weeks; randomization method not
discussed.

No effect at 52 weeks on postprandial
serum triglycerides, chylomicron
triglycerides, free fatty acids, lipoprotein
lipase, or hepatic lipase after a fatty
meal.

2

Emmelot-Vonk
et al, 2008[91]

237 healthy men 60–80 years old with T
concentration below the median; ie, <13.7
nM (395 ng/dL); 30 dropouts, 16 of whom
provided some follow-up information.

160 mg T undecanoate (n = 120) or
placebo (n = 117) by mouth daily for 6
months; randomization by computergenerated list using blocks of 6.

No effect on total, HDL, or LDL
cholesterol or triglycerides.

5

Kalinchenko et al,
2010[162]

184 men, 35–69 years old, with metabolic
syndrome and T concentration <12.0 nM
(346 ng/dL); 14 dropouts were eliminated
from analysis.

1000 mg T undecanoate (n = 113) or
placebo (n = 71) IM at 0, 6, and 18 weeks;
randomization method not discussed, tx
arms were intentionally uneven.

No difference in total, HDL, or LDL
cholesterol or in triglycerides.

4

Jones et al, 2011
[26]

220 men, mean age 59.9 years, with
metabolic syndrome or T2DM or both and
total T 11 mM (317 mg/dL) or free T
<255 pM (7.3 ng/dL); 54% of subjects
completed the study, ITT analysis used
last observation carried forward.

60 mg T (n = 108) or placebo (n = 112) gel
for 12 months; randomization stratified by
presence of metabolic syndrome only,
diabetes mellitus (DM) only, and DM with
metabolic syndrome; dose levels adjusted
based on T measurements.

#LP-a (23–27%) at months 6 and 9; no
difference at month 12; No difference in
total, HDL, or LDL cholesterol or in
triglycerides

4

Paduch et al, 2015
[78]

Sexually active men 26 or more years old
with ejaculatory dysfunction and total
T < 300 ng/dL (10.41 nM).

T solution applied to axilla daily at 60
No differences in total, LDL, or HDL
(n = 39) or 0 (n = 35) mg/day, titrated up or cholesterol or triglycerides
down based on serum T concentration
after 4 weeks. Computer randomization
scheme on a 1:1 basis. Five subjects in
each group discontinued, 1 in T group due
to adverse event.

5

Basaria et al, 2015
[6]

Men aged 60 years or older, morning total
T 100–400 ng/dL (3.5–14 nM) or free <50
testosterone pg/mL (1.7 pM). 1:1
concealed randomization with
stratification by age dichotomized at 75
years and by site. Computer-generated
randomization. All subjects receiving at
least 1 medication dose were retained for
analysis.

3 years of daily application of 75 (n = 155)
or 0 (n = 151) mg testosterone as a gel,
dose level adjusted upwards or
downwards based on total testosterone
2–12 hours after gel application. Placebo
adjusted by an unblinded observer. 44/
155 randomized to T did not complete, 23
for adverse events; 51/151 receiving
placebo did not complete, 17 for adverse
events.

No differences in total, LDL, or HDL
cholesterol or triglycerides

5

Asih et al, 2015
[163]

50 men 50 years old complaining of
T transdermal 50 (n = 22) or 0 (n-22)
memory problems (44 completed)
applied to the scrotum daily for 24 weeks;
Randomization by random numbers table. after a 4-week washout, patients were
crossed over to the other arm

No differences in total, HDL, or LDL
cholesterol.

5

Webb et al, 2008[3] 25 men 40–75 years old with
angiographically proven coronary heart
disease (70% lesion in at least one
major coronary artery or major branch),
plasma T concentration 12 nM (346 ng/
dL); 2 dropouts prior to medication tx were
not analyzed. One subject had
unanalyzable data.

(Continued)
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Table 1. (Continued)
INFLAMMATORY AND COAGULATION MARKERS
Ng et al, 2002[33]

37 healthy men >60 years of age with
serum T concentration <15 nM (432 ng/
dL); 4 dropouts were excluded from
analysis.

DHT gel 70 mg/day (n = 18) or placebo
(n = 19) for 3 months.

No effect on C-reactive protein, soluble
intracellular adhesion molecule-1, or
soluble vascular cell adhesion molecule1.

Malkin et al, 2004
[27]

29 men 36–78 years old with a clinical
indication for T replacement for
hypogonadism; 2 subjects were
withdrawn and 2 additional patients did
not contribute analyzable sera.

100 mg T (n = 27) or placebo IM (n = 27)
every 2 weeks; randomization using
blocks of computer-generated numbers. A
crossover design appears likely, although
not explicit.

#Serum tumor necrosis factor-α (TNF-α). 5
"Interleukin-10 (IL-10). No change in IL1β (identified as decreased by authors,
but not statistically significant).

Malkin et al, 2004
[1]

12 men 60.8 ± 4.6 years old (mean ± SD)
with CAD and “clinical need for T
replacement”; one man failed screening,
one man withdrew at unspecified point in
the study.[19]

100 mg T or placebo IM every 2 weeks x 4 #Serum TNF-α.
weeks, 1 month washout, then tx switch;
randomization by computer; described as
single-blinded.

Smith et al, 2005
[34]

61 men with CAD recruited, 50 completed 5 mg T or placebo patches applied each
screening and placebo run-in phase. Four night.
subjects withdrew and were excluded
from analysis.

No change in plasma fibrinogen,
plasminogen activator inhibitor-1, or
tissue plasminogen activator at 6 or 14
weeks tx.

3

Pugh et al, 2005
[21]

12 men 48–82 years old with stable CHF
(same group reported on in 2003)[19]

60 mg T or placebo given buccally
followed the next day by tx switch.
Described as randomized, but
randomization method not given.

No effect on serum concentration of
TNF-α with any of these T tx.

3

20 men with NY Heart Association class II
or III CHF, mean age 63.9 years in the
active group and 61.1 years in the
placebo group.

100 mg T (n = 10) or placebo (n = 10) IM
every 2 weeks for 12 weeks. Subjects said
to be randomized, randomization method
not given.

3

62 men with NY Heart Association class
II, III, or IV CHF, mean age 63.1 years in
the active group and 64.9 years in the
placebo group.

5 mg T (n = 37) or placebo (n = 39) patch
applied daily for 12 weeks. Randomization
method not given.

3

20 men, 52–76 years old (mean age 63
years) with T2DM and total T <12 nM (346
ng/dL) or bioavailable T <4 nM (115 ng/
dL) with symptoms attributed to
hypogonadism; 4 men were excluded due
to technical problems with measurement.

200 mg Sustanon (30 mg T propionate, 60 No effect on C-reactive protein.
mg T phenylpropionate, 60 mg T
isocaproate, and 100 mg/mL T
decanoate) or placebo IM every 2 weeks
for 6 injections followed by a 1-month
washout followed by tx switch; tx order
randomized by computer-derived random
number table; number in each arm not
stated.

5

Kapoor et al, 2007
[31]

4

5

Webb et al, 2008[3] 25 men age 40–75 with angiographically
160 mg/day T undecanoate or placebo by
proven CAD (70% lesion in at least one mouth for 8 weeks followed by tx switch.
major coronary artery or major branch),
Randomization method not given.
plasma T concentration 12 nM (346 ng/
dL); 2 dropouts prior to medication tx were
not analyzed. One subject had
unanalyzable data.

No change in plasminogen activator-1,
fibrinogen, or factor VII.

4

Guler et al, 2006
[28]

41 men with CAD who underwent
stenting.

3 weekly IM doses of T (n = 25; Sustanon
250 = T propionate 30 mg,
phenylproprionate 60 mg, isocaproate 60
mg, and decanoate 100 mg); 3-week
interval before stenting with usual tx
(n = 16). Described as double-blind, but
no placebo injection discussed.
Randomization method not given.

24 hours after stenting,#interleukin-6 (IL6), #C-reactive protein. No effect on
TNF-α.

2

Nakhai-Pour et al,
2007[29]

237 men age 60–80 with serum T
concentration below the population
median (13.7 nM); 14 were lost to followup.

160 mg daily T undecanoate 160 mg/day
(n = 113) or placebo (n = 110).
Randomization methods not given.

No effect of tx on C-reactive protein,
except " in men with baseline C-reactive
protein concentration below the median.

5

(Continued)

PLOS ONE | DOI:10.1371/journal.pone.0162480 September 21, 2016

10 / 46

Testosterone Systematic Review

Table 1. (Continued)
Frederiksen et al,
2012[30]

38 men age 60–78 with free T
concentration <7.3 nM finished the study.
Number starting not given.

Gianatti et al, 2014 88 men age 35–70 years of age with a
[32]
history of T2DM and total testosterone
12.0 nML (346 ng/dL). 13 men did not
complete the study, 8 because of
intensification of oral hypoglycemic
agents or commencement of insulin
therapy. 1 subject in testosterone group
was withdrawn with a hematocrit of >54
prior to his 30 week injection.

Unspecified dose of T gel or placebo used #Osteoprotegerin. No change in Cfor 6 months.
reactive protein.

3

Participants were randomly assigned in a No change in CRP concentration.
concealed 1:1 allocation to T or placebo
using permuted blocks with a block size of
4. IM T undecanoate 1000 mg (n = 45) or
placebo (n = 43) at 0, 6, 18, and 30 weeks.

4

doi:10.1371/journal.pone.0162480.t001

3.1.2 Congestive heart failure. Six studies evaluated effects of testosterone treatment on
CHF.[18–23] In two papers from the same group,[19, 20] it is not clear whether treatments
were randomly assigned. Administration of testosterone by the buccal route was associated
with beneficial effects on cardiac index and systemic vascular index in the acute catheterization
setting, consistent with an acute vasodilatory effect.[19] Intramuscular (IM) testosterone treatment for 12 weeks improved exercise capacity and reduced heart failure symptom scores without identifiable effects on left ventricular size or ejection fraction (EF).[20] Another study of
IM testosterone in men with CHF showed an improvement in oxygen consumption, respiratory efficiency (ventilation/carbon dioxide consumption), and distance walked in 10 minutes
without changes in EF or left ventricular end-diastolic diameter.[18] The improvements in
exercise function appeared attributable to the response of men with baseline plasma testosterone concentration <12 ng/mL (~4 nM). A study of a testosterone patch showed improvement
in the shuttle walk test.[23] Another study showed no effect of IM testosterone enanthate on
ejection fraction, although there was an improvement in a Doppler-based myocardial performance index.[22]
The only study that scored above a 3 on Jadad found a benefit on CHF measures.[18]
3.1.3 Lipids. Serum or plasma concentrations of cholesterol fractions, triglycerides, and
lipoproteins have been used as surrogate endpoints for cardiovascular risk, although they
should not be mistaken for markers of cardiovascular adverse events. In 25 studies, testosterone
treatment was associated with favorable, unfavorable, or no effects on lipids as summarized in
Table 1. Favorable effects in 11 studies included 5–11% decreases in total cholesterol concentration and variable and inconsistent decreases in triglycerides and low-density lipoprotein
(LDL) cholesterol. One of the studies counted as showing a favorable effect did not demonstrate a change in total or high-density lipoprotein (HDL) cholesterol or triglycerides but
reported a 13% reduction in LDL cholesterol.[24] This finding was based on averages of several
repeated measurements over the course of 1 year rather than a determination of improved
lipid measurements at the end of the treatment period.
Unfavorable changes were reported in 2 studies [5, 25] and included increases in total cholesterol, LDL cholesterol, and triglycerides and decreases in HDL cholesterol in men evaluated
as hypogonadal prior to androgen therapy. Most of the studies that did not report favorable
effects of testosterone on lipids reported no effects at all. One of these studies[26] reported a
decrease in lipoprotein-a (LP-a), but this finding was transient and occurred in a study with
multiple measurements at multiple time points in multiple patient subgroups without adjustment for multiple comparisons. Nine of the 11 studies that had favorable effects on lipids had
Jadad scores of 4 or 5. Nine of the 14 studies that lacked favorable effects on lipids had Jadad
scores of 4 or 5.
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The discordance between studies on the lipid effects of testosterone treatment did not
appear to be route dependent. Seven of the 11 studies showing favorable effects used IM injection of testosterone enanthate, esters, or undecanoate. Five of the 14 studies not showing favorable effects on lipids used IM injection of testosterone esters, cypionate, or undecanoate.
3.1.4 Inflammatory or coagulation markers. Eleven studies were identified in which
markers that have been associated with atherosclerotic cardiovascular disease risk were measured in men using testosterone or dihydrotestosterone therapy. Three studies reported favorable effects of testosterone on tumor necrosis factor-α (TNF-α), a marker of inflammation.[1,
3, 27] One study in men with CHF showed no effect of testosterone treatment by buccal, IM,
or transdermal routes on serum concentration of TNF-α.[21] One of the studies asserted that
there was a decrease in the inflammatory marker interleukin-1β (IL-1β), but a statistically significant effect was not shown.[1] Another study showed a decrease in interleukin-6 (IL-6) and
C-reactive protein, additional inflammatory markers.[28] Two studies performed in elderly
men who were largely without a diagnosis of CAD showed no beneficial effect of testosterone
therapy on C-reactive protein[29, 30] as did two studies of men with type 2 diabetes mellitus.
[31, 32] Transdermal dihydrotestosterone did not affect inflammatory markers in men with
low total pretreatment testosterone concentrations.[33] No change in fibrinogen, plasminogen
activator inhibitor-1, or tissue plasminogen activator was shown in men with CAD who used
testosterone patches or oral doses.[3, 34]

3.2 Sexual Function
The 48 studies that assessed sexual function or libido as a primary or secondary endpoint are
summarized in Table 2. Study populations included men identified by study authors as “hypogonadal,” normal men, and men with erectile dysfunction (ED). Studies included men with
depression,[35–37] chronic renal disease,[38] cirrhosis,[39] arterial insufficiency,[40] cancer,
[24] diabetes,[26] HIV,[35, 41] Alzheimer disease,[42] and chronic obstructive pulmonary disease (COPD).[43] Preparations included IM (n = 16), oral (n = 11), topical gel or solution
(n = 14), patch (n = 5), and buccal (n = 1) formulations. Studies used a variety of questionnaires, including the International Index of Erectile Function (IIEF), Frenken sexual experience
scales, Derogatis Sexual Performance Scale (DSPS), the Aging Males’ Symptoms (AMS) scale,
Male Sexual Health Questionnaire, Psychosexual Daily Questionnaire, and study-specific questionnaires. Study reports used different language for symptoms, so we grouped, for example,
“libido,” “sexual interest,” and “sexual desire.”
Of 47 studies that assessed sexual function or satisfaction, 23 studies reported beneficial
effects of testosterone treatment for at least 1 measure of sexual function or satisfaction,[6, 26,
35, 37, 40, 43–60] and 24 studies did not show testosterone-associated improvements in any
sexual function endpoint.[24, 36, 38, 39, 41, 42, 61–78] Three studies we counted as positive
were mixed: Steidle et al found improvement with 100 but not 40 mg of gel, Legros et al[57]
tested 3 dose levels of orally administered testosterone undecanoate (60 mg, 160 mg, and 240
mg) and found a benefit only for the middle dose, and Hackett et al[58] found that testosterone
worked in a group with testosterone 8.0 nM for intercourse satisfaction but not in a group
with testosterone 8.1–12 nM. One study “reported a subjective feeling of increased muscular
energy and sexual desire in some subjects”.[79] There was no difference between groups by
Fischer exact test (performed by us) and we excluded this study from further analysis. Limiting
analysis to the 30 studies with Jadad scores of 4 or 5 yielded similar results; 14 were positive
and 16 negative.
Of 31 studies that evaluated erectile function, 15 found no improvement with testosterone
therapy,[6, 26, 39, 41, 55, 59, 62, 64, 65, 68, 70–72, 76, 77] and 16 reported a benefit.
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Table 2. Effects of Testosterone on Sexual Functioning.
Hentzer & Madsen,
1967[40]

39 males with arterial insufficiency; 3
dropouts.

200 mg T (n = 19) or placebo (n = 17) IM
weekly for 3 weeks, then once every
second week for 6 months;
consecutively enrolled patients assigned
alternately to T or placebo by record
numbers.

Improved sexual function in 9 Ttreated (n = 19) and 2 placebo-treated
(n = 17) men (Fisher P = 0.03
calculated by us, not by authors).

3

Benkert et al, 1979[62]

36 men 45–75 (mean age 56.5) with
erectile dysfunction (ED); 7 men
withdrew, 2 in the placebo group and 5 in
the T group.

120 mg/day T undecanoate (80 mg qam
and 40 mg qpm; n = 18) or placebo
(n = 18) PO for 8 weeks; 2-week placebo
run-in; 2-week placebo withdrawal
phase, and 8 additional weeks of
observation.

No difference from placebo in ability to 3
have an erection or sexual satisfaction
(both groups improved).

Davidson et al, 1979
[44]

6 hypogonadal men with T <150 ng/dL
(5.2 nM).

Crossover, within-subject, 3 phase
design. T enanthate 0, 100, or 400 mg IM
each administered once, a month apart.
Tx were administered in “arbitrarily
chosen order and “varied at random
within and among subjects.”

400 mg dose improved total erections,
nocturnal erections, and coital
frequency. No effect on incidence of
orgasm or masturbation.

3

Skakkebaek et al,
1981[45]

12 men 22–48 years old diagnosed as
androgen deficient; one man
subsequently found to be normal and
excluded.

160 mg T undecanoate or placebo daily
by mouth for 2 months followed by tx
switch; randomization of order of tx not
described but said to be balanced.

"Sexual acts and ejaculations per
week. "Frequency of sexual thoughts
and excitement. No effect on
subjective quality of sexual act.
Subjective ratings of sexual
enjoyment, erectile and ejaculatory
problems improved.

3

Nankin et al, 1986[46]

10 men 51–74 years old with secondary
200 mg T cypionate or placebo IM every
impotence and T concentrations <420 ng/ 2 weeks for 12 weeks followed by the
dL (14.6 nM).
opposite tx; no washout period
mentioned, randomization of tx order not
described.

"Libido and potency based in part on
scores assigned to questionnaire
responses analyzed using t-test;
insufficient detail provided to permit
nonparametric analysis of ranked
data.

4

Gluud et al, 1988[39]

221 alcoholic men 24–79 years old
(median age 53) with cirrhosis; dropouts
not described but range of follow-up was
1–48 months; results for 110 men were
included at 30 months.

600 mg T (not otherwise specified) in
divided doses or placebo by mouth daily
for a median of 30 months;
randomization 3:2 (T:placebo); no other
details about number in each group or
randomization method.

No effect on libido, erectile or
ejaculatory function.

3

Anderson et al, 1992
[63]

31 healthy men, 21–41 years old in a
male contraceptive study.

200 mg T enanthate (n = 16) or placebo
(n = 15) IM weekly for 4 weeks (n = 16);
continuation of study with T in place of
placebo not discussed here;
randomization method not given.

"Sexual interest on the psychosocial
2
stimulation scale of the 4-part Frenken
Sexual Experience Scales (FSES). No
effect on the other 3 parts of the
FSES. No effect on masturbation,
intercourse or waking erection.

Holmäng et al, 1993
[79]

25 obese men 40–65 years old, mean
age 52years; 2 dropped out, 1 in each
group.

320 mg T undecanoate or placebo daily
for 8 months; randomization procedure
not described.

Five in the T group (n = 11) vs 1 in the
placebo group (n = 12), “reported a
subjective feeling of increased
muscular energy and sexual desire.”
No other details provided. (Fischer’s
exact test not significant when
performed by us; not analyzed by
authors.)

4

Aydin et al, 1996[64]

79 men (mean age 34.2–39.5) with nonorganic ED; unclear how many withdrew.

120 mg/day T undecanoate (n = 20) or
placebo (n = 18) daily presumably by
mouth (trazodone and hypnosis arms not
discussed here); 12- and 16-week
results not represented due to high
dropout rate; study analyzed only at 4
and 8 weeks; randomization method not
given.

At 8 weeks, 8 in the T group (n = 20)
and 6 in the placebo group (n = 18)
were considered “cured;” 4 T vs 1
placebo experienced a moderate
response; and 8 T vs 11 placebo had
no response (χ not significant by us;
not analyzed by authors).

2

(Continued)
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Table 2. (Continued)
Schiavi et al, 1997[59]

18 men 46–67 years old (median age 60
years) with ED with or without hypoactive
sexual desire; 12 men completed the
study, dropouts were excluded from
analysis.

200 mg T enanthate or placebo IM every
2 weeks for 6 weeks followed by 4-week
washout followed by the opposite tx;
order was randomized by unstated
method; 7 subjects received placebo
first, 5 subjects received T first.

No effect on sexual satisfaction,
frequency of sexual desire,
masturbation, sex with partner,
morning erections, or degree of
erections. "Ejaculations.

3

Dobs et al, 1998[65]

13 men with T concentrations <250 ng/dL
(8.7 nM) who had previously received IM
T therapy; 1 man dropped out after 4
weeks.

10 mg T or taste-matched placebo
(pseudoephedrine 3 mg) buccal tablet
daily for 4 weeks; doubling of dose
permitted after end of first 4 weeks;
randomization method not given.

No effect on total scores of Watts
Sexual Function Questionnaire
(WSFQ) after 8 weeks; "Frequency of
sexual desire and morning erections,
but not erections in general;
"Maximum rigidity and duration of full
nocturnal penile tumescence
assessed in a sleep lab.

3

Rabkin et al, 2000[35]

74 HIV-positive men, mean age 39, with
serum T <17.4 nM (501 ng/dL) with
sexual dysfunction and at least one
“hypogonadal” mood symptom; 3
subjects in the placebo group dropped
out, 1 in T group was excluded from
analysis because of medication error.
Among the 70 subjects analyzed, 26 had
major depressive disorder (MDD),
dysthymia, “minor” depression, or MDD in
remission.

Randomization in blocks of 4 by
computer-generated numbers to T
cypionate (n = 38 overall, 26 with
depression diagnosis) or placebo (n = 32
overall, 7 with a depression diagnosis)
injected biweekly (presumably IM) for 6
weeks; the first T dose was 200 mg,
subsequent doses were 400 mg. Openlabel phase with T followed the 6-week
double-blind study and is not
summarized here.

"Libido and morning erections.
Testosterone improved ED by
expanded CGI (Clinical Global Index)
among completers with initial ED.

4

Seidman et al, 2001
[36]* Seidman &
Roose, 2006[164]

32 men 33–71 years old with MDD
200 mg T enanthate (n = 13) or placebo
(DSM-IV criteria) and serum T 350 ng/
(n = 17) IM weekly for 6 weeks.
dL (12.1 nM); 2 dropouts in the T group
Randomization method not mentioned.
and 1 in the placebo group were excluded
from analysis.

No effect on Derogatis Sexual
Performance Scale (DSPS).

4

Howell et al, 2001[24]

35 men mean age 40.9 years with some
degree of testicular dysfunction after
cytotoxic cancer therapy; blood LH
concentration 8 mIU/L and T
concentration <20 nM (576 ng/dL); 2
dropouts, 1 in each group, were excluded
from analysis.

2.5 or 5.0 mg T patch (n = 16) or placebo
patch (n = 19) daily for 12 months;
randomization method not described,
study described as single-blind.

No effect on interest in sex, sexual
activity, or frequency of erections.

3

Park et al, 2003[66]

39 men with sexual dysfunction, infertility,
symptoms of hypogonadism and T <400
ng/dL (13.9 nM); 4 subjects in the T group
dropped out.

160 mg T undecanoate (n = 33) or
placebo (n = 6) daily by mouth for 3
months; described as single-blind,
randomization method not given.

Between-group analyses not reported. 2
Fischer’s exact test as performed by
us showed no significant difference
between groups in showing sexual
function improvement. Androgen
Deficiency in the Aging Male (ADAM)
questionnaire scores reported
improvement only in the treated group,
but total scores not provided.

Aversa et al, 2003[47]

20 men 48–66 years old (mean 56 years
old) with arteriogenic ED and T 10–13 nM
(288–375 ng/dL) and free T 200–300 pM
(5.8–8.6 ng/dL) who had not responded
to sildenafil.

5 mg transdermal T (n = 10) or placebo
(n = 10) patch daily for 1 month; all
subjects received sildenafil 100 mg to
use on demand; randomization method
not given.

Improved overall erectile function
3
domain score, intercourse satisfaction,
overall satisfaction, number of acts of
sexual intercourse, and percentage of
successful intercourse attempts.
Improved erections in 8 men on T
(n = 10) and 1 on placebo (n = 8). No
change in sexual desire and orgasmic
function.
(Continued)
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Table 2. (Continued)
Steidle et al, 2003[56]

406 hypogonadal men 20–80 years old,
mean age 60.5 years in T group, 56.8
years in placebo group, with T
concentration 10.4 nM (300 ng/dL) and
at least one symptom of fatigue,
decreased muscle mass, reduced libido,
or reduced sexual functioning; 6 patients
in the T gel group discontinued because
of AEs.

50–100 mg T (n = 99; 43 titrated up to
100 mg) or 100 mg (n = 106; 4 titrated
down to 50 mg) or placebo (n = 99) gel
daily for 90 days; dose titration took
place at 60 days; randomization method
not given; open-label portion of study not
discussed here.

4
100 mg group, but not 50 mg group,
was superior to placebo for
spontaneous erections, sexual
motivation, desire, and performance at
90 days. No change in sexual
enjoyment with or without a partner,
satisfaction with erection duration, or
percentage of full erection.

Cavallini et al, 2004
[48]

150 men >50 years old with symptoms
consistent with hypogonadism and free T
<6 pg/mL (21 pM); 20 dropouts analyzed
by ITT.

160 mg/day T undecanoate (n = 40),
propionyl-L-carnitine 2 g/day plus acetylL-carnitine 2 g/day (n = 45), or placebo
(n = 45) presumably by mouth for 6
months; randomization method not
given.

"Erectile function at 3 and 6 months,
sexual desire at 3 but not 6 months,
and sexual intercourse satisfaction at
6 but not 3 months. No change in
general sexual well-being or orgasm.
Carnitine superior to T for erectile
function at 3 and 6 months and for
orgasm and general sexual well-being
at 6 but not 3 months.

4

O’Connor et al, 2004
[67]

28 healthy eugonadal men 22–44 years
old; 4 subjects treated with T withdrew
and were excluded.

1000 mg T undecanoate or placebo IM at
the beginning of an 8-week phase,
followed by 8-week washout, followed by
the opposite tx, randomization of tx order
not described.

No effect on frequency of sexual
intercourse, masturbation, sexual
desire, enjoyment of intercourse, or
overall satisfaction with sexual
experience on weekly logs.

3

Shabsigh et al 2004
[69]

75 hypogonadal men 41–66 years old
with T 400 ng/dL (13.9 nM) with ED who
had failed to respond to sildenafil; 12
subjects withdrew, 5 in placebo group, 7
in T group.

1% T (n = 39) or placebo (n = 36) gel as
adjunctive therapy to sildenafil 100 mg
for 12 weeks, randomization by
computer generated schedule stratified
by researcher.

No effect on mean change from
baseline in total International Index of
Erectile Function (IIEF) scores and
erectile function, orgasmic function,
and overall satisfaction domains at 8
weeks or 12 weeks. No differences
between groups in average number of
successful sexual attempts or selfassessed improvement in erection.

5

Svartberg et al, 2004
[43]

29 men, mean age 67.5 years in the
placebo group, 64.5 years in the T group
with moderate to severe COPD; 2
dropped out, 1 in each group.

250 mg T (n = 15) or placebo (n = 14) IM
every 4 weeks for 26 weeks; method of
randomization not discussed.

Improved score on IIEF and improved
erectile function. "Sexual quality of life
at 12 but not 26 weeks.

4

Haren et al, 2005[69]

76 men 60–86 years old, mean age 68.5
years with  2 “androgen deficiency”
symptoms, total T >8 nM (231 ng/dL) and
free T index between 0.3 and 0.5.

80 mg T undecanoate or placebo PO
twice daily for 12 months, number in
each group unclear, randomization with
a block of 4 was used “in the Almedica
drug labeling system (ADLS).”

No effect on symptom change from
baseline.

4

Brockenbrough et al,
2006[38]

40 men with anemia of chronic renal
disease (mean age 59 years in T group
and 53 years in placebo group) on
erythropoietin with serum T <300 ng/dL
(10.4 nM); 10 withdrew in the placebo
group and 8 withdrew in the T group.

T 100 mg (n = 19) or placebo (n = 21) gel
daily for 6 months; block randomization
in groups of four stratified by
erythropoietin dose at 250 U/kg/week;
details of randomization not given.

No effect on sexual function, desire,
relationships, or behavior.

5

Lu et al, 2006[42]

47 men (18 with Alzheimer disease (AD)
and 29 healthy men); mean age 69.3
years (T) and 70.3 years (placebo) in
those with AD; 63.6 years (T) and 61.2
years (placebo) in healthy men; 6/23 in T
group and 3/25 in placebo group
withdrew.

75 mg T gel (n = 9 with AD and 14
healthy men) or placebo (n = 9 with AD
and 15 healthy men) gel daily for 24
weeks; method of randomization not
given.

No effect on sexual functioning, by the
modified Change in Sexual
Functioning Questionnaire (CSFQ).
Caretakers of AD patients reported no
sexual behavior changes.

3

Merza et al, 2006[49]

39 men 44–77.4 years old, mean age 62
years, with sexual dysfunction and total T
<10 nM (288 ng/dL) or free androgen
index <30%; 8 patients withdrew, 4 in
each group.

T patch 5 g/day (n = 20) or placebo patch
(n = 19) for 6 months; randomization list
“generated by Biostatistical Department
at Ferring AB.”

Significant difference between groups
in Male Erectile Dysfunction Quality of
Life questionnaire (MEDQoL) due to
decrement in placebo group (no
change from baseline in patch group).

3

(Continued)
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Table 2. (Continued)
Chiang et al, 2007[50]

40 men 20–74 years old with serum T
<300 ng/dL (10.4 nM) or free T <8.7 pg/
mL (30 pM); 4 subjects withdrew, all in
placebo group.

T 50 mg (n = 20) or placebo (n = 20) gel
daily for 3 months; randomization
method not given.

"Sexual function on comparison made 3
to baseline. No effect on magnitude of
score increase with t-test performed
by us.

Chung et al, 2007[61]

30 healthy men 18–45 years old.

T 200 mg mixed esters (n = 10) or
placebo (n = 10) IM weekly for 4 weeks;
nandrolone arm not discussed here;
computer-generated randomization in
blocks of 6.

No effect on sexual function.

5

Allan et al, 2008[70]

62 healthy men 55 (mean age 62.1
years in the placebo group and 64.5
years in placebo group) with serum T <15
nM (432 ng/dL); 14 in the treated group
and 6 in placebo group dropped out.

5 mg transdermal T (n = 31) or placebo
(n = 31) patch daily for 52 weeks.
Subjects randomized in a 1:1 ratio;
randomization method not given.

"Sexual desire at 26 and 52 weeks.
No effect on any erectile function,
orgasmic function, intercourse
satisfaction, overall satisfaction.

5

Knapp et al, 2008[41]

61 HIV-positive men, mean age 43 years,
with involuntary weight loss and/or bodymass index <20 mg/m2; 4 placeboassigned and 9 T-assigned subjects
dropped out and were analyzed using the
last observation carried forward.

300 mg T enanthate (n = 31) or placebo
(n = 30) weekly for 16 weeks;
randomized by computer-generated list
in blocks of 6.

No difference between groups in
5
sexual function assessed by a
5-question scale: 1) “I found it easy to
achieve an erection when I wanted to”;
2) “I have lost interest in sex”; 3) “I
found it difficult to sustain an erection
when I wanted to”; 4) “I had problems
achieving an orgasm”; and 5) “I am
generally satisfied with the sex that I
have.”

Emmelot-Vonk et al,
2009[71]

237 healthy men, 60–80 years old (mean
67) with T <13.7 nM (395 ng/dL); 30
dropped out; 16 in T group, 14 in placebo
group.

160 mg T undecanoate (n = 120) or
placebo (n = 117) in divided daily oral
doses for 26 weeks; randomization
computer-generated using blocks of 6
(Emmelot-Vonk et al[91]).

No effect on sexual functioning
including frequency of sexual activity,
quality of sexual functioning, and
ability to achieve or maintain erection.

Legros et al, 2009[57]

322 men 50 years old with symptoms of
hypogonadism and calculated free T
<0.26 nM (7.5 ng/dL); 243 completed,
310 analyzed for efficacy, 39
discontinued due to AEs and 22 withdrew
consent; no marked difference between
groups in discontinuation rates.

PO T undecanoate 0 (n = 79), 80
(n = 78), 160 (n = 82), or 240 mg (n = 77)
daily for 12 months; randomized in
unstratified blocks.

Improved sexual symptoms subscale 4
score of Aging Males Symptoms
(AMS) scale only in middle dose group
(160 mg/day).

5

Morales et al, 2009[72] 86 men 45–70 years old with sexual
dysfunction and T <12 nM (346 ng/dL); 7
withdrew; 5 in T group, one each in DHEA
and placebo groups.

160 mg T undecanoate (n = 29) or
No effect on IIEF, ADAM, AMS, or
placebo (n = 29) daily by mouth for 4
Global Assessment Questionnaire
months; DHEA arm not further discussed (GAQ).
here; randomization in permuted blocks
of 9.

5

Seidman et al, 2009
[51]

23 men, mean age 50.6 years, with
dysthymia and serum T concentration
<350 ng/dL (12.1 nM).

T cypionate 200 mg (n = 13) or placebo
(n = 10) IM every 10 days for 6 weeks;
randomization by computer.

A significant time by tx interaction in
5
the IIEF total score demonstrable in all
sexual function domains, but no data
provided.

Buvat et al, 2011[55]

223 men with ED and total T 4 ng/mL
(13.9 nM) or bioavailable T 1 ng/mL (3.5
nM) who had not responded adequately
to highest dose of a phosphodiesterase
inhibitor; 35 withdrawals (20 placebo, 15
T).

After 4-week valdenafil run-in, patients
randomized to T 50 mg (n = 83) or
placebo (n = 84) gel daily for 12 weeks;
dose doubled to 100 mg at 4 or 8 weeks
based on clinical response;
randomization prepared by
manufacturer, method not given.

No improvement in erectile function by 3
intention-to-treat (ITT) analysis (both
groups improved). "Intercourse
satisfaction in men with baseline T <3
ng/mL (10.4 nM) in post hoc analysis.

Giltay et al, 2010[52]

184 men 35–69 years old (mean 52.1
years old) with T concentration <12.0 nM
(346 ng/dL) or calculated free T
concentration <225 pM (6.5 ng/dL) who
had metabolic syndrome; 14 dropouts (8
T, 6 placebo) were analyzed using last
observation carried forward.

T undecanoate 1000 mg (n = 113) or
placebo (n = 71) IM given every week 0,
6, 18, and 24; evaluations at week 30.
Randomization method not given except
to say that T was over-assigned in a 7:3
ratio.

"AMS scale and IIEF

4

(Continued)
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Table 2. (Continued)
Srinivas-Shankar
et al, 2010[53]

274 frail men, mean age 74 years, with
total T 12 nM (346 ng/dL) or free T
250 pM (7.2 ng/dL); 31 withdrawals, 15
placebo, 16 T.

50 mg T (n = 138) or placebo (n = 136)
gel daily for 6 months; day 10 and 3
months adjusted to 25–75 mg based on
T; computerized randomization in blocks
of 10.

"AMS sexual domain based on
adjusted differences between groups;
total AMS scores not provided.

5

Amiaz et al, 2011[37]

100 depressed men age 30–65 (mean
50.7 in placebo group, 51.5 in treated
group) treated with serotonergic
antidepressants, with serum T <350 ng/
dL (12.1 nM); data lost (n = 26); 5
withdrew, and 6 apparently had
incomplete records.

T gel (amount and dose not described;
"Erectile function, intercourse
n = 50) or placebo gel (n = 50) for 6
satisfaction, orgasmic function, sexual
weeks; randomization by table of random desire, overall satisfaction, total IIEF.
numbers with a blocked design of 50.

5

Ho et al, 2011[73]

120 Malaysian men age 40–70 (mean 53)
with "mild" symptoms on AMS scale and
total T <12 nM (346 ng/dL); 8 dropouts, 4
per group.

1000 mg T undecanoate (n = 56) or
placebo (n = 58) IM at week 0, 6, 18, 30,
and 42; randomization method not
described

No effect on the AMS sexual domain
scores. Total scores improved.

4

Jones et al, 2011[26]

220 men, mean age 59.9, with metabolic
syndrome or T2DM or both and total T
11 nM (317 ng/dL) or free T <255 pM
(7.3 ng/dL); 54% of subjects completed
the study, ITT analysis used last
observation carried forward.

60 mg T (n = 108) or placebo (n = 112)
gel for 12 months; randomization
stratified by presence of metabolic
syndrome only, DM only, and DM with
metabolic syndrome; doses adjusted
based on T measurements.

Improved sexual desire, intercourse
satisfaction, and total IIEF scores. No
effect on AMS, erectile or orgasmic
function, or overall sexual satisfaction
scores.

4

Spitzer et al, 2012[74]

140 men 40–70 years old, mean age 55.1
years for T group, 54.6 years for placebo
group, with low erectile function scores
and total T concentrations <11.45 nM
(330 ng/dL) or free T concentrations
<173.35 pM (5 ng/dL); 22 dropped out, 10
T and 12 placebo.

5–15 g T 1% gel (n = 70) or placebo
(n = 70) gel daily for 14 weeks;
randomization sequence used blocks of
4; other details not provided; all subjects
received sildenafil.

No effect of T on sexual function,
assessed by questionnaires,
frequency of sexual encounters,
percentage of successful sexual
intercourse, and other measures.

5

Del Fabbro et al, 2013
[75]

43 men with advanced cancer and
bioavailable T <70 ng/dL (2.4 nM),
hemoglobin >9 g/dL, Eastern Cooperative
Oncology Group performance status <3,
and moderate to severe fatigue; 3
placebo and 5 T (1 died) dropped out.

T enanthate 150 or 200 mg (depending
on weight; n = 19) or placebo (n = 24) IM
every 2 weeks for 2 months. Doses
titrated to a bioavailable T goal of 70–
270 ng/dL (2.4–9.4 nM).

No change on Sexual Desire Inventory 4
(SDI) (P = 0.054).

Hackett et al, 2013[54]

199 men, mean age 61.6 years, with total
T 8.1–12 nM (233–346 ng/dL) or free T
0.181–0.25 nM (5.2–7.2 ng/dL) or total T
8.0 nM (231 ng/dL) or free T 0.18 nM
(5.2 ng/dL); 9 dropouts, 4 in the active
group and 5 in placebo group.

T undecanoate 1000 mg (n = 97) or
placebo (n = 102) IM at weeks 0, 6, and
18; evaluated at 18 & 30 weeks;
randomized in unstratified blocks.

At 30 weeks, "erectile function,
5
intercourse satisfaction, sexual desire,
orgasm; no effect on overall
satisfaction; no changes in AMS.

Men aged 60 years or older, morning total
T 100–400 ng/dL (3.5–14 nM) or free T
<50 pg/mL (1.7 pM). 1:1 concealed
randomization with stratification by age
dichotomized at 75 years and by site.
Computer-generated randomization. All
subjects receiving at least 1 medication
dose were retained for analysis.

3 years of daily application of 75
(n = 155) or 0 (n = 151) mg testosterone
as a gel, dose level adjusted upwards or
downwards based on total testosterone
2–12 hours after gel application. Placebo
adjusted by an unblinded observer. 44/
155 receiving T did not complete, 23 for
adverse events; 51/151 receiving
placebo did not complete, 17 for adverse
events.

No difference in IIEF total score or
subscales except intercourse
satisfaction increased more with T
than with placebo

Sexually active men 26 or more years old
with ejaculatory dysfunction and total T<
300 ng/dL (10.41 mM).

T solution applied to axilla daily at 60
(n = 39) or 0 (n = 35) mg/day, titrated up
or down based on serum T concentration
after 4 weeks. Computer randomization
scheme on a 1:1 basis. Five subjects in
each group discontinued, 1 in T group
due to adverse event.

No difference in changes in Male
5
Sexual Health QuestionnaireEjaculatory Dysfunction-Short Form or
individual components of the total
score; No change in ejaculate volume;
No differences in ejaculation or
orgasm components of the IIEF; No
differences in sexual activity log

Basaria et al, 2015[6]

Paduch et al, 2015[78]

At 18 weeks, "intercourse satisfaction,
sexual desire, and orgasm; no effect
on ED, overall satisfaction; or AMS.
5

No difference in marital interaction
scale from the Cancer Rehabilitation
Evaluation System Short Form

(Continued)
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Table 2. (Continued)
Snyder et al, 2016[60]

790 men 65 with a serum total T
concentration of <275 ng/dL and
symptoms suggesting hypoandrogenism.
705 completed.

T gel (1%) or placebo x 1 year. Initial
dose was 5 g daily but dose was
adjusted to keep T concentration within
range for young men. Dose was
changed simultaneously in subject taking
placebo. Number of subjects in each arm
cannot be determined.

" sexual activity; " sexual desire and
erectile function; No benefit on vitality
assessed by Functional Assessment
of Chronic Illness Therapy-Fatigue
scale; No benefit on physical function.

2

Basaria et al, 2015[77]

84 men, 18–64 using opioid analgesics
for chronic noncancer pain, with a
morning serum total T concentration of
<350 ng/dL (12 nM)

T gel (1%) 5 (n = 43) or 0 (n = 41) g daily
x 3 months. In T group, dose adjusted at
two weeks by unblinded physician if T
<500 ng/dL. Unblinded physician then
increased dose of a participant in the
placebo group. Study completion by 36
on T and 29 on placebo.

"Desire; No effect on erectile function
or orgasmic domain of IIEF.

4

Gianatti et al, 2014[76] 88 men with T2DM, age 35–70, with total T undecanoate 1000 (n = 44) or 0
testosterone <346 ng/dL (12 nM), aging
(n = 41) mg IM at week 0, 6, 18, and 30,
male symptoms, and erectile dysfunction; randomized using permuted blocks.
75 completed.

4
No improvement in Aging Males
Symptoms total score, sexual
subscore, or sexual desire. Restriction
of analysis to symptomatic men
revealed no difference. Erectile
function was reduced compared with
placebo, but no change compared to
baseline.

Hackett et al, 2014[58]

Improvement in erectile function,
5
intercourse satisfaction, sexual desire,
and AMS in group starting with total T
8.0 nM; Improved AMS score but no
improvement in sexual function in
group starting with total T between 8.1
and 12 nM.

199 men aged 18–80 with T2DM with
total T between 8.1–12 nM (233–346 ng/
dL) or total T of 8.0 nM (231 ng/mL). 9
patients did not complete the study; 4
because of serious adverse events (3
treatment unrelated deaths, 1 prostate
cancer in placebo), and 5 withdrew their
consent.

Subjects were block randomized to
receive testosterone undecanoate 1000
(n = 97) or 0 (n = 102) mg IM at week 0,
6, and 18.

doi:10.1371/journal.pone.0162480.t002

[35, 37, 43–52, 56, 58, 60] Although the study by Chiang et al[50] reported a benefit of both testosterone and placebo compared to baseline; however, our analysis did not show a difference
between treatment groups. Limiting analysis to the 17 studies with Jadad scores of 4 or 5
yielded similar results; 9 were positive and 8 were negative.
Twelve studies included men with ED; 8 found no benefit of testosterone over placebo,[55,
59, 62, 64, 68, 72, 74, 76] and 4 found a benefit.[35, 46, 47, 49] One negative study found that
testosterone reduced erectile function when compared to placebo; however, there was no
change when each group was compared to its baseline.[76]
Of 23 studies that specifically reported changes in libido, 13 found that testosterone treatment increased libido,[26, 35, 37, 45, 46, 54, 56, 60, 63, 65, 70, 77, 79] eight found no effect,[24,
38, 39, 47, 59, 67, 75, 76] and 1 found an effect after 3 but not 6 months of treatment.[48] Hackett et al[58] found that testosterone improved sexual desire in a group with initial testosterone
8.0 nM but not in a group with initial testosterone 8.1–12 nM.
Eleven studies used the Aging Males’ Symptoms scale, which includes 3 questions on libido
and sexual function. Five studies found no difference between testosterone and placebo on
total scores,[26, 54, 57, 72, 76] and 4 studies found a benefit of testosterone.[52, 57, 58, 66]
One paper[53] reported only sexual subscales but not total AMS scores. On the sexual subscale of the AMS scale, this study reported a benefit, Ho et al[73] found no benefit, and Legros
et al[57] found a benefit of testosterone on the AMS sexual subscale only in the middle (160
mg) of 3 dose levels at 3 of 4 time points. Hackett et al[58] found that testosterone improved
AMS scores in a group with initial testosterone 8.0 nM but not in a group with initial testosterone 8.1–12 nM.
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Ten of 13 of the studies on libido or desire with a Jadad score of 4 or 5 found a benefit.
Seven of 12 studies on erectile dysfunction with a Jadad score of 4 or 5 found a benefit.

3.3 Muscle Weakness/Wasting
Table 3 summarizes 39 studies that evaluated the effect of testosterone on physical function,
muscle strength, or HIV-associated muscle wasting, including 19 in men assessed as having
low serum testosterone, 9 on HIV-negative men with normal serum testosterone, 1 on healthy
men with normal serum testosterone, and 10 on HIV-positive men. Studies that measured testosterone effects only on body composition (other than in HIV-associated wasting) without
measures of physical function or muscle strength were excluded. Subjects included both those
defined by the authors as hypogonadal and those considered to have normal testosterone concentrations. Common measures of muscle strength included grip strength dynamometry and
the 1-repetition maximum for exercises including the bench press and leg press. Physical function was often measured by the 6-minute walk test, the time and number of steps required to
walk 25 feet, and the get-up-and-go test, which evaluates the ability to rise from a chair, walk a
short distance, and return to sitting.
Twenty studies evaluated subjects described as hypogonadal, with 11 of those evaluating
healthy subjects. Five studies examined the effects of testosterone supplementation on physical
frailty, functional limitations, or a categorization as “sedentary,”[53, 80–83] and single studies
evaluated subjects with COPD,[84] advanced cancer,[75] and Parkinson’s disease.[85] Ten
studies evaluated subjects considered to have normal testosterone concentrations; 1 study
included healthy, elderly men, and the remainder included subjects with planned knee replacement surgery,[86] stable CHF,[18, 22, 87] leg claudication or ulcers,[13] long-term glucocorticoid therapy,[88] myotonic dystrophy,[89] arterial insufficiency,[40] COPD,[43] or who were
planning or undergoing physical rehabilitation.[90]
Ten studies evaluated subjects with HIV; 8 of those studies included subjects with HIVwasting, 1 included subjects with abdominal obesity, and 1 did not use weight criteria. Most of
these papers studied older men. Few studies investigated the use of testosterone supplementation in men younger than 60 years.
Twenty-seven studies measured the effects of testosterone treatment on muscle mass, with
22 (81%) of these studies showing a significant increase in muscle mass associated with treatment.[41, 43, 53, 80–84, 88, 89, 91–102] Nineteen of 22 (86.3%) of these studies had a Jadad
score of 4 or 5. Twenty-five studies assessed the effects of testosterone treatment on fat mass,
with 15 (60%) of these studies showing a decrease in fat mass associated with treatment.[11, 43,
53, 81, 83, 84, 88, 91, 93, 94, 96, 97, 99, 102, 103] Twelve of these studies had a Jadad score of 4
or 5.
Some studies did not measure muscle and fat mass specifically but used other body composition endpoints. Two studies showed no changes in body weight or BMI,[22, 104] but another
showed an increase in body weight and BMI.[18] One study, with a Jadad score of 3, showed
no change in weight or estimates of body fat (triceps and scapula skinfold thickness).[105] In
studies of HIV-positive men with weight loss, 3 of 6 studies (all of which had Jadad scores of 4
or 5) showed an increase in weight with testosterone treatment,[99, 101, 106] and all 4 studies
that measured muscle mass showed an increase.[41, 99–101]
Of the 30 studies that assessed muscle strength as a primary or secondary endpoint, 13 studies (43%) reported an improvement in at least 1 measure of muscle strength.[11, 18, 53, 81, 83,
84, 88, 93, 94, 101, 102, 104, 107] Eleven of 13 of these studies had a Jadad score of 4 or 5.
Three of these 12 studies (all with Jadad scores of 4 or 5) reported improvements in fewer than
25% of the measurements.[11, 53, 81] In studies of men without HIV, 11 of 24 studies (45.8%)
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Table 3. Effects of Testosterone on Muscle Weakness/Wasting.
MEN ASSESSED AS HAVING LOW SERUM TESTOSTERONE
Brill et al, 2002
[92]

10 men 60–78 years old with morning
serum T 200–450 ng/dL (6.9–15.6 nM),
serum prolactin below 25 μg/L, LH and
FSH below 20 IU/L, IGF-I below 200 μg/
L.

T patch 5 mg/day or placebo x 1 month
with each subject serving as his own
control; subjects also received growth
hormone with or without T (not discussed
here); randomization method not given.

No change in eccentric/concentric knee
extension/flexion strength, hamstring
flexibility, or eyes-closed non-dominantleg balance test. "Fat-free mass by 1 of 2
measurement techniques. No change in
% body fat or BMI.

3

Casaburi et al,
2004[84]

53 men 55–80 years old with COPD
(FEV1 60% of predicted, FEV1: VC
ratio 60%) and serum T 400 ng/dL
(13.9 nM); 6 dropouts were excluded
from analysis.

T enanthate 100 mg (n = 23) or placebo
(n = 24) IM weekly with or without
resistance training x10 weeks;
randomization method not given.

T + no training group: Compared to
placebo + training: "trunk lean mass, #%
fat. Compared to placebo groups: "arm
and total lean mass; #leg and total fat.
Compared to placebo + no training: "leg
lean mass and leg press strength; #leg
press fatigue and peak work rate. No
change: arm and trunk fat, maximal
inspiratory pressure, peak O2 uptake,
lactic acidosis threshold, constant work
rate duration.

5

T + strength training group: Compared to
placebo groups: "arm, trunk, leg, and
total lean mass; #leg, total, and % fat.
Compared to non-training groups: "leg
press strength and peak oxygen uptake;
#leg press fatigue. Compared to T + no
training: "peak work rate. Compared to
placebo + no training: "lactic acidosis
threshold. No change: arm and trunk fat,
maximum inspiratory pressure, constant
work rate duration.
Clague et al, 1999 14 men mean age 68.1 with total T <400
[165]
ng/dL (13.9 nM).

T enanthate 200 mg (n = 7) or placebo
(n = 7) IM every 2 weeks x 12 weeks, with
muscle testing every 4 weeks;
randomization method not given.

No change in handgrip, knee extensor,
and knee flexor strength, leg extensor
power, step height.

4

Emmelot-Vonk
et al, 2008[91]

237 men 60–80 years old with total T
T undecanoate 80 mg (n = 120) or placebo
<395 ng/dL (13.7 nM); 30 dropouts were (n = 117) capsules twice daily x 6 months;
excluded from analysis.
a randomization list without stratification
using blocks of 6 was computer-generated
using the ADLS.

#Total body fat mass and body fat
percentage; "total body lean mass. No
change in grip strength, leg extensor
strength, timed get up and go test.; No
change in BMI, intra-abdominal fat mass.

5

Ferrando et al,
2001[93]

12 healthy men, mean age 67–68 with
serum total T 480 ng/dL (16.7 nM).

No change at 1 month in strength. At 6
months: "strength for bicep curl, tricep
extension, leg extension. No change in
leg-curl strength and knee extension
endurance in the dominant leg. "Total
lean body mass, leg lean mass, leg
muscle volume; #fasting protein
breakdown % body fat. No change in arm
lean mass

0

T enanthate (n = 7) or placebo (n = 5) IM
(dosage adjusted to maintain nadir serum
T concentrations 17–28 nM) weekly x 1
month, then every 2 weeks x 6 months;
randomization method not given.

(Continued)

PLOS ONE | DOI:10.1371/journal.pone.0162480 September 21, 2016

20 / 46

Testosterone Systematic Review

Table 3. (Continued)
Hildreth et al,
2013[94]

167 men over 60 years old (mean age
66) with total T 200–350 ng/dL (6.9–12.1
nM); 24 dropouts were excluded from
analysis.

T gel 1% 2.5, 5.0 g (n = 111), or placebo
(n = 56) daily x 12 months, with or without
progressive resistance exercise training;
randomization was performed using
permuted block randomization with
random block sizes.

5
T treated groups analyzed in aggregate.
In subjects with resistance training, no
change in physical functional
performance tests: upper body strength
and flexibility, lower body strength,
balance, and endurance, stair climb
speed and 6-min walk, strength (bench
press, incline press, overhead pull-down,
seated row, average upper body, grip
strength, knee extension, knee flexion,
seated leg press, average lower body),
power (leg extensor). #Fat mass; "overall
and arm fat free mass. No change in
weight, BMI, trunk fat mass, appendicular
and leg fat-free mass, waist and hip
circumferenceIn subjects without PRT:
"Lower body strength, strength for bench
and incline press, average upper body
and grip strength. No change in physical
functional performance test total score,
upper body strength and flexibility, lower
body balance and endurance, stair climb
speed and 6-min walk, strength for
overhead pull-down, seated row, knee
extension/flexion, seated leg press, and
average lower body, power (leg
extensor). "Appendicular and arm fat free
mass. #Overall and trunk fat mass, waist
circumference. No change in weight,
BMI, overall and leg fat-free mass, hip
circumference

Kenny et al, 2001
[166]

67 men >65 years old (mean age 76)
with bioavailable T <128 ng/dL (4.44
nM); 23 dropouts were excluded from
analysis.

T patch 5 mg (n = 34) or placebo (n = 33)
daily x 1 year; all received 500 mg calcium
and 400 IU vitamin D supplements;
randomization method not given.

No change in BMI, % body fat or lean
mass. No change in PASE (Physical
Activity Scale for the Elderly) score.
PASE includes 8-ft walk speed, chair
rise, single-leg stance, supine-to-stand,
and get up and go time.

4

Kenny et al, 2010
[80]

131 men 60 years old (mean age 77.1)
with T <350 ng/dL (12.1 nM), physical
frailty, and BMD T-score at the hip  —
2.0 or a nontraumatic fracture within last
5 years; delays in recruitment and lack
of funds resulted in 16 months of
follow-up with analysis performed at 12
months; 69 dropouts excluded from
analysis.

T gel 5 mg (n = 69) or placebo (n = 62)
daily x 16 months; all subjects maintained
calcium intake of 1500 mg/day and were
given 1000 IU cholecalciferol/day;
randomization with block sizes (2 or 4)
stratified by frailty status

"Total body lean mass, appendicular
skeletal muscle mass; No change in total
body fat %. No change in hand grip/ leg
press strength or PASE

5

Ly et al, 2001[11]

37 healthy men >60 years old (mean
age 68.2) with plasma T 429 ng/dL
(14.9 nM); 4 dropouts were excluded
from analysis or for some measures,
missing data imputed using last
observation carried forward

0.7% DHT gel 70 mg (n = 17) or placebo
(n = 16) daily x 3 months, followed by 1
month of observation; method of
randomization inadequately explained

"Dominant knee flexion peak torque from 5
2–4 months. No change in waist:hip ratio,
lean mass, peak torque for knee
extension, nondominant knee flexion,
shoulder flexion/extension, maximal
horizontal forward reach of the
outstretched right arm without losing
balance; standing balance time with feet
tandem, eyes closed, 18 meter fast walk,
time to stand up and sit 5x. #Body weight
(month 4), fat mass (months 2–4),
skinfold thickness (months 2–4).
(Continued)
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Table 3. (Continued)
Nair et al, 2006
[95]

62 men >60 years old with bioavailable
T <3.6 nM (104 ng/dL); incomplete
follow-up for some subjects, 4 subjects
did not complete study.

Transdermal T patch 5 mg (n = 30) or
placebo (n = 32) x 24 months;
randomization method not given.
Additional arms included women and
included other tx (not discussed here)

No change in peak VO2, peak torque of
isometric dominant knee extension,
strength for seated chest press and
double leg press. "Fat-free mass. No
change in body weight, BMI, body fat %,
visceral:total fat ratio, visceral fat, thighmuscle area

4

Okun et al, 2006
[85]

30 men mean age 68 with Parkinson
disease and free T <100 pg/mL (347
pM).

200 mg T enanthate (n = 15) or placebo
(n = 15) IM every 2 weeks x 8 weeks; dose
could be adjusted upwards based on free
T measured every 2 weeks; randomization
method not given.

No change in motor function as
measured by a videotaped Unified
Parkinson’s Disease Rating Scale
(UPDRS) evaluation.

4

Page et al, 2005
[81]

48 men age 65–83 (mean 71) with
morning serum total T <350 ng/dL (12.1
nM), classified as sedentary (60 min/
week of moderate-intensity recreational
physical activity); 13 dropouts excluded
from analysis

T enanthate 200 mg (n = 24) or placebo
(n = 24) IM every 2 weeks x 36 months;
subjects also received T with finasteride
(not discussed here); randomization
method not given

"Improvement in timed physical
performance, right handgrip strength. No
change in body weight, left handgrip
strength, peak torques of knee/ankle
flexion/extension. #Total fat mass, %
body fat, right leg fat, trunk fat. "Lean
body mass, waist:hip circumference ratio

4

Sih et al, 1997
[104]

32 men (mean age 68 for placebo and
65 for T) with bioavailable blood T 60
ng/dL (2.1 nM); 3 T subjects dropped
due to an abnormal increase in
hematocrit of 52%

T cypionate 200 mg (n = 17) or placebo
"Grip strength. No change in body
(n = 15) IM every 14–17 days x 12 months; weight, BMI
randomization by random number

4

Srinivas-Shankar
et al, 2010[53]

297 men 65 years old (mean age 73)
with physical frailty and total T 345 ng/
dL (12 nM); 31 dropouts excluded from
analysis

T 50 mg (n = 136) or placebo (n = 138) gel
daily x 6 months; dosage adjusted if T
concentrations remained outside the target
range (18–30 nM); subjects randomized in
blocks of 10 by computer-generated
sequence

"Isometric knee extension peak
torque"LBM, #fat mass. No change in
isokinetic knee extension peak torque,
isometric/ isokinetic knee flexion peak
torque, grip strength, aggregate
locomotor function (ALF) test, physical
performance test (PPT), 6 minute walk,
PASE, Tinetti gait/balance test.

5

Snyder et al, 1999 108 men >65 years old with serum T
T patch 6 mg (n = 54) or placebo (n = 54)
[96]
<495 ng/dL (17.2 nM); 12 dropouts were daily x 36 months; every 3 months T
excluded from analysis.
concentration was checked and dosage
was decreased to 4 mg/day if serum T was
>1000 ng/dL; randomization method not
given.

No change in weight, BMI, tissue mass,
trunk fat mass, arm/leg lean mass,
strength for knee extension/ flexion and
handgrip, time to walk and number of
steps in 25 feet, time to walk 12 stairs.
#Fat mass, arm/leg fat mass. "Lean
mass, trunk lean mass

4

Sullivan et al,
2005[82]

71 men 65 years old (mean age 78.2)
with serum total T <480 ng/dL (16.7 nM)
and a recent functional decline; 10
dropouts were excluded from analysis.

T enanthate 100 mg (n = 37) or placebo
(n = 34) IM weekly with low- or highintensity resistance strength training x 12
weeks; randomization stratified by
arbitrary score of physical ability; within
each stratum, subjects randomized with
blocks sizes in multiples of 4 and randomly
varied

No change in strength for chest and leg
press, performance testing score (sit-tostand maneuver, habitual and maximal
safe gait speed tests, stair climb). "Midthigh cross-sectional muscle area

5

Travison et al,
2011[83]

209 men 65 years old with total serum
T 100–350 ng/dL (3.5–12.1 nM) or free
serum T <50 pg/mL (174 pM) with
mobility limitations; analysis restricted to
165 men with a baseline assessment
and at least one outcome assessment.

T 100 mg (n = 106) or placebo (n = 103)
gel daily x 6 months; after 2 weeks, dose
level was increased or decreased by 50%
based on serum T; randomization by
computer-generated table in blocks of 6
stratified by age

"Strength for leg and chest press, loaded
stair-climbing power, loaded walk speed.
No change in grip strength, unloaded
walking speed, unloaded stair-climbing
power. "Total lean mass, appendicular
skeletal muscle mass. #Total fat mass,
appendicular fat mass. "Cardiovascularrelated AEs with T (23 vs 5)

5

(Continued)
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Table 3. (Continued)
Wittert et al, 2003
[97]

76 healthy men age 60 (mean 68.5)
with 2 symptoms on the ADAM
questionnaire, a ratio of T/sex-hormone
binding globulin of 0.3–0.5, serum total
T >230 ng/dL (8 nM); 18 dropouts were
excluded from analysis.

T undecanoate 80 mg (n = 39) or placebo
(n = 37) twice daily x 12 months;
randomization with blocks of 4 as part of a
proprietary system

No change in grip, quadriceps, and calf
strength;No change in body weight.
"Lean body mass; #% body fat

5

Borst et al, 2014
[167]

60 men 60 years old with serum
testosterone concentration 300 ng/dL
(10.4 nM) or bioavailable testosterone
70 ng/dl (2.4 nM). 40 completed.
Randomized by computer program

4 groups: T enanthate 125 mg/ week IM X
52 weeks and finasteride 5 mg/day; T
enanthate and oral placebo; vehicle i.m
and finasteride, or vehicle IM and placebo.

Testosterone, compared to finasteride or
placebo, increased strength (leg press,
knee flexion and extension, chest press,
triceps extension, and grip strength),
body fat-free mass. Total fat mass
reduced 3.87 kg. Lumbar spine and hip
BMD increased

5

Amory et al, 2002
[86]

25 men 58–86 years old undergoing
knee replacement surgery; 3 dropouts
were excluded from analysis.

T enanthate 600 mg (n = 10) or placebo
(n = 12) IM 21, 14, 7, and 1 day before
surgery; randomized using a random
number sequence.

"Standing function at post-operative day 5
3. No change in standing function at postoperative day 35, walking and stair
climbing tests, length of hospital stay

Bakhshi et al,
2000[90]

15 men 65 years old who had been
admitted to the Geriatric Evaluation and
Management unit for rehabilitation; 1
subject in the T group died unexpectedly
2 weeks after admission on the day of
his planned discharge probably as the
result of a cardiovascular event.

T enanthate 100 mg (n = 9) or placebo
(n = 6) IM weekly until discharge or for a
maximum of 8 weeks; subjects received
rehabilitation therapy as appropriate to
their needs; randomization method not
given.

"Functional Independence Measure and
grip strength compared to baseline;
difference compared to placebo not
reported, but no difference in either
endpoint compared to placebo by t-test
performed by us.

4

Caminiti et al,
2009[18];
Schwartz et al,
2011[87]

70 men 66–76 years old (mean age 70)
with stable CHF (NYHA II or III) and LV
EF <40%; 6 dropouts (4 on T and 2 on
placebo) were excluded from analysis.

T undecanoate 1000 mg (n = 35) or saline
(n = 35) IM at 6 and 12 weeks. Subjects
said to be randomized, randomization
method not given

"Peak VO2, peak workload, distance
walked in 6 minutes, leg muscle strength,
knee extension/flexion peak torque.
#Ventilation/CO2 output. "Body weight,
BMI

4,
5

Dohn et al, 1968
[13]

44 men with leg claudication or ulcers
attributed to arteriosclerosis in 43 men
and to Buerger’s disease in 1 man; age
not given. Two men did not complete
study. Numbers in tables add to 86
subjects. Not possible to tell for sure
how many men were analyzed.

Aqueous T isobutyrate 300 mg or
meprobamate as placebo every 14 days
for 3 months; route of administration not
given; double-blinded, randomization not
discussed

No effect on subject improvement,
walking test

3

Crawford et al,
2003[88]

43 men >20 years old (mean age 60.3)
on long-term glucocorticoid therapy; 14
dropouts were excluded from analysis.

T mixed esters 200 mg (n = 18) or placebo
(n = 16) IM every 2 weeks x 12 months; all
received calcium carbonate 600 mg daily;
randomization method not given.
Nandrolone not discussed.

"Peak knee extension/flexion torque.
"Lean mass. #Fat mass. No change in
body weight, BMI, waist circumference,
waist:hip ratio, skinfold thickness.

3

Griggs et al, 1989
[89]

40 men 18–65 years old (mean age 33.3
years for T and 41.5 years for placebo)
with myotonic dystrophy and a typical
distribution of weakness (but
ambulatory); 3 dropouts were excluded
from analysis.

T enanthate or placebo 3 mg/kg IM weekly
x 12 months; number of subjects/group not
given; evaluations every 3 months;
randomization performed using computergenerated random numbers, stratified by
grip strength and previous T tx

"Time to climb stairs. No change in arm
4
volume, weight, manual muscle testing,
myometry, grip dynamometry, forced vital
capacity (VC), maximum voluntary
ventilation, maximum expiratory
pressure, time to walk 30 feet, time to cut
standard square. "Creatinine excretion
("muscle mass)

Hentzer &
Madsen, 1967[40]

39 males with arterial insufficiency; 3
drop outs.

200 mg T (n = 19) or placebo (n = 17) IM
weekly for 3 weeks, then once every
second week for 6 months; consecutive
patients assigned to tx or placebo by
record numbers.

No change in grip strength, walking
distance.

3

Svartberg et al,
2004[43]

29 men 54–75 years old (mean age 66
T enanthate 250 mg (n = 15) or placebo
years) with moderate to severe COPD; 2 (n = 14) IM every 4 weeks x 26 weeks;
dropouts were excluded from analysis.
method of randomization not discussed

No change in BMI, forced VC, forced
expiratory volume, 6-minute walk. "Fatfree mass. #Total body fat mass (at 12
weeks).

4

HIV-NEGATIVE MEN WITH NORMAL SERUM TESTOSTERONE

(Continued)
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Table 3. (Continued)
Mirdamadi et al,
2014[22]

50 males age 50–70 with CHF

T enanthate 250 mg IM or saline placebo
IM every 4 weeks for 12 weeks

No difference between groups in muscle
strength or body weight. Both groups
improved in 6-minute walking distance;
no post-intervention effect was seen.

3

Giannoulis et al,
2006[168]

Healthy men 65–80 years old with
circulating IGF-I <50th percentile for the
local age-specific range; of those
meeting criteria, the 80 subjects with the
lowest T concentration but without T
deficiency, mean 397.6 ng/dL (13.8 nM);
5 subjects were excluded because PSA
concentrations met revised exclusion
criteria and 6 dropouts were excluded
from analysis.

T 5 mg or placebo transdermal patch daily
x 6 months; randomization was performed
using computer-generated pre-allocated
study numbers; growth hormone arm not
discussed here

No change in knee flexion/extension
peak torque/force, hand-grip peak force,
VO2 max. No change in BMI, hip/waist
ratio, lean body mass, subcutaneous/
cross-sectional abdominal visceral/total
body fat, mid-thigh muscle cross
sectional area.

5

HIV-POSITIVE MEN
Bhasin et al, 2007 88 HIV-positive men 18–70 years old
[98]
with abdominal obesity and serum total
T 125–400 ng/dL (4.3–13.9 nM); 8
dropouts were excluded from analysis.

Transdermal T gel 100 mg (n = 44) or
placebo (n = 44) daily x 24 weeks;
randomization stratified by RNA copy
number with approximate balance within
each site

#Total abdominal, subcutaneous
abdominal, trunk, extremity, and whole
body fat mass; waist circumference;
waist:hip ratio. "Trunk, extremity, and
total lean mass. No change in visceral fat
area, body weight, BMI

5

Bhasin et al, 1998 41 HIV-positive men 18–60 years old
[103]
with serum T <400 ng/dL (13.9 nM); 9
dropouts were excluded from analysis.

T patch 5 mg (n = 20) or placebo (n = 21)
daily x 12 weeks; randomization method
not given

No change in strength (squat and bench
press); #Fat mass. No change in lean
body mass (LBM), fat-free mass, total
body weight

3

Bhasin et al, 2000 61 HIV-positive men 18–50 years old
[99]
with involuntary weight loss, serum total
T <349 ng/dL (12.1 nM); 12 dropouts
were excluded from analysis.

T enanthate 100 mg (n = 32) or placebo
(n = 29) IV x 16 weeks with or without
resistance exercise; randomization by
random number table stratified by age in
blocks of 16.

4
T with no-exercise group: no change in
strength for leg press, leg curls, bench
press, latissimus pulls, overhead press;
"Body weight, muscle volume; no change
in fat-free and fat mass, total body water
(TBW), TBW:fat-free mass ratio, LBM of
arms/legs/trunk. T with exercise group:
no changes in any measure

Coodley et al,
1997[105]

39 HIV-positive men 18–60 years old
with AIDS and weight loss; 4 dropouts
were excluded from analysis.

T cypionate 200 mg (n = 17) or placebo
(n = 18) IM every 2 weeks x 3 months
followed by tx switch x 3 months;
randomization method not given

No change in weight, triceps and scapula
skinfold

3

Dobs et al, 1999
[113]

133 men with AIDS age 18–65+ who
had lost 5–20% of baseline weight with a
morning serum total T concentration
400 ng/dL (13.9 nM) or free T
concentration 16 pg/mL (56 pM); 15 T
and 20 placebo subjects did not
complete.

T 15-mg (n = 67) or placebo (n = 66) patch
applied 20–24 hours/day to shaved scrotal
skin for 12 weeks; assessments at weeks
4, 8, and 12; randomization method not
given

No effect on body cell mass or weight.

3

Fairfield et al,
2001[107]

54 HIV-positive men (mean age 38
years) with normal serum free T >12 pg/
dL (0.4 pM) and wasting; 11 dropouts
were excluded from analysis.

T 200 mg (n = 24) or placebo (n = 26) IM
weekly with or without progressive
resistance training x 12 weeks; patients
were stratified by body weight, but
randomization method not given

"Thigh muscle attenuation on
4
computerized tomography (CT) only in
subjects who received training. Strength
testing was evaluated only with respect to
attenuation by CT, not tx group.

Grinspoon et al,
1998[100]

51 HIV-positive men mean age 42 with
free T <11.9 pg/dL (0.4 pM) and
wasting; 11 dropouts were excluded
from analysis.

T enanthate 300 mg (n = 21) or placebo
(n = 19) IM every 3 weeks x 6 months;
subjects stratified by body weight and
megestrol acetate use; randomization
using a permuted block algorithm

No change in fat mass, TBW, exercise
performance (6-minute walk test, timed
sit-to-stand test, timed get-up-and-go
test). "Fat-free mass, LBM, muscle
mass, total body potassium content

5

Grinspoon et al,
2000[101]

54 HIV-positive men with wasting and
serum free T >42 pM (1.2 ng/dL); 11
dropouts were excluded from analysis.

T enanthate 200 mg (n = 24) or placebo
(n = 26) IM weekly x 12 weeks with
progressive strength training + aerobic
conditioning or no training; randomization
with permuted-block algorithm (blocks of
8).

"Peak isometric force for shoulder
extension and elbow flexion. No change
in peak isometric force for knee flexion/
extension and dorsiflexion. Grip strength
results were not reported. "Weight, LBM,
arm muscle area, leg muscle area

5

(Continued)
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Table 3. (Continued)
Knapp et al, 2008
[41]

61 HIV-positive men 18–60 years old
(mean age 43) with unintentional weight
loss or BMI <20 and serum T <400 ng/
dL (13.9 nM); 4 placebo-assigned and 9
T-assigned subjects dropped out and
were analyzed using the last
observation carried forward.

T enanthate 300 mg (n = 30) or placebo
(n = 31) IM weekly x 16 weeks; computergenerated randomization list with a block
size of 6

No change in physical function measures
(stair-climbing power, walking speed,
load-carrying ability), muscle
performance (leg press strength, leg
press power, leg press fatigability). "Fatfree mass. No change in fat mass, total
weight, % body fat.

Sardar et al, 2010
[106]

104 HIV-positive men >18 years old with
involuntary weight loss or BMI <20;
randomized subjects evaluated using
ITT analysis.

Sustanon 250 = T propionate 30 mg,
phenylproprionate 60 mg, isocaproate 60
mg, and decanoate 100 mg (n = 42) or
placebo (n = 20) IM every 2 weeks x 12
weeks; computer-generated
randomization tables in a 2:1 ratio

"Weight. No change in BMI, waist and hip 5
circumference, waist:hip ratio, triceps
and scapula skinfold thickness, mid-arm
circumference, % body fat

5

doi:10.1371/journal.pone.0162480.t003

reported an improvement in at least 1 measure of muscle strength. In studies of men with HIV,
2[101, 107] of 5 studies reported an improvement in at least 1 measure of muscle strength; 3
showed no effect.[41, 99, 103]
Twenty-four studies evaluated the effects of testosterone treatment on physical function
endpoints and, of these, 5 found an improvement in at least 1 measure of function.[18, 22, 81,
83, 86] Neither of the 2 studies of HIV patients measuring physical function showed an
improvement in function.[41, 100] Six of these studies had a Jadad score of 4 or 5.[18, 41, 81,
83, 86, 100]
In summary, the majority of studies show increased muscle mass but no effect of testosterone on muscle strength or function.

3.4 Mood and Behavior
Forty-five studies evaluating the effect of testosterone on mood and behavior are summarized
in Table 4. Twenty-nine of these studies focused on men without psychiatric disorders, and 16
on men with psychiatric disorders.
3.4.1 Healthy men. Some studies of mood and behavior were designed to evaluate the
potential adverse effects of anabolic steroid abuse. For example, men abusing anabolic steroids
have been described as having “Roid Rage.” We did not evaluate steroid abuse studies, but we
reviewed studies on testosterone preparations and their association with anger, aggression, and
other mood alterations. There was little consistency among the studies we reviewed.
Five studies reported treatment-associated increases in anger, aggression, or hostility.[67,
108–111] Only two of these studies had a Jadad score of 4 or 5.[108, 111] One study,[110] with
a Jadad score of 3, determined that testosterone gel applied to the skin increased hostility based
on evaluations by 2 undergraduate judges of a free-text paragraph written by each subject to
describe his mood at the end of treatment. We do not know the reliability of this assessment.
Two studies (Jadad score 3 and 5) reported a decrease in anxiety after testosterone treatment.
[45, 112]
Seventeen of 29 studies reported no effect of testosterone treatment on personality, psychological well-being, or mood.[22, 24, 38, 59, 63, 85, 104, 113–121] Seven of 17 studies had a
Jadad score of 4 or 5. One of these studies could not be evaluated because only a composite
score for mood and sexual function was reported.[38] The study that used hostility assessments
by undergraduate judges found no change in personality as assessed by the Gough and Heilbrun Adjective Check List.[110] Another study in this group reported that elevation of testosterone serum concentrations above normal using testosterone gel was associated with an
increase in selfishness on a computer game that evaluated the willingness to give away small
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Table 4. Effects of Testosterone on Mood and Behavior.
MEN WITHOUT PSYCHIATRIC DISORDERS
Skakkebaek et al,
1981[45]

12 men 22–48 years old diagnosed
as androgen deficient; one man
subsequently found to be normal and
excluded.

T undecanoate 160 mg or placebo daily
for 2 months followed by opposite tx;
randomization of tx order not described
but said to be balanced.

Improved self-rated anxiety and tension;
no statistically significant effect on
depression, anger, vigor, or fatigue
(authors concluded otherwise based on
P = .10).

3

Anderson et al, 1992
[63]

31 healthy men 21–41 years old.

T enanthate 200 mg IM weekly for 8
(n = 16) or 4 weeks with placebo IM
weekly for the remaining 4 weeks
(n = 15); randomization not discussed.
Described as single-blinded.

No effect on self-assessment of mood
(cheerful, lethargic, relaxed, tense,
energetic, unhappy, irritable, ready to
fight, easily angered) using an
unvalidated ranking scale.

2

Janowsky et al, 1994
[114]

56 healthy men 60–75 years old.

T 15-mg scrotal (n = 27) or placebo patch No effect on self-rated or spouse-rated
(n = 29) 16 hours daily for 3 months;
Profile of Mood States (POMS).
method of randomization not discussed.

Kouri et al, 1995[108]

8 healthy men 20–39 years old; 2
were subsequently excluded from
analysis because they did not accept
the terms of the test situation.

Crossover design: 1) T cypionate IM 150
mg/week for 2 weeks, then 300 mg/week
for 2 weeks, then 600 mg/week for 2
weeks then no tx for 6 weeks, then
placebo IM for 6 weeks, then no tx for 6
weeks or 2) Same design with placebo tx
prior to T.

"Aggressive response to a buttonpushing game involving retaliation
against a fictitious opponent. "Young
Mania Rating Scale score (more
aggressive).

4

Bhasin et al, 1996
[115]; Tricker et al,
1996[116]

50 healthy men 19–40 years old who
had earlier experience with weightlifting; 7 dropped out prior to
randomization, 3 dropped out during
tx and were excluded.

T enanthate 600 mg or placebo IM
weekly followed by the opposite tx, tx for
10 weeks followed by washout. Further
randomization within tx to exercise or
non-exercise. Randomization method not
given.

No effect on Multidimensional Anger
Inventory, Mood Inventory, or Observer
Mood Inventory administered prior to tx
and during weeks 6 and 10, 7 days after
previous injection.

2,
4

Schiavi et al, 1997[59]

18 men 46–67 years old (median age
60 years) with ED with or without
hypoactive sexual desire; 12 men
completed the study, dropouts were
excluded from analysis.

T enanthate 200 mg or placebo IM every
2 weeks for 6 weeks followed by 4-week
washout followed by the opposite tx;
order was randomized by unstated
method; 7 subjects received placebo
first, 5 subjects received T first.

No effect on POMS or psychological
symptom profile.

3

Sih et al, 1997[104]

32 men 51–79 years old with free
blood T concentration <60 ng/dL (2.1
nM); unclear how dropouts after
randomization were handled.

T cypionate 200 mg (n = 10) or placebo
No effect on Yesavage Geriatric
(n = 12) every 14–17 days for 12 months; Depression Scale (GDS)
tx allocation by random number (not
otherwise characterized)

4

Dobs et al, 1999[113]

133 men with AIDS age 18–65+ who
had lost 5–20% of baseline weight
with a morning serum total T
concentration 400 ng/dL (13.9 nM)
or free T concentration 16 pg/mL
(56 pM); 15 T and 20 placebo did not
complete the study.

T 15-mg (n = 67) or placebo (n = 66)
patch applied 20–24 hours/day to shaved
scrotal skin for 12 weeks; assessments
at weeks 4, 8, and 12; randomization
method not given.

No effect on health distress or mood
assessed by Rand HIV-Medical
Outcomes Study-short form or
EUROQoL Feeling Thermometer

3

Pope et al, 2000[169]

53 presumed healthy men aged 20–
50 years; an additional 13 men were
recruited but not randomized or were
randomized and not evaluable.

T or placebo IM every 2 weeks. T dose
was 150 mg/week for 2 weeks, 300 mg/
week for 2 weeks, and 600 mg/week for 2
weeks. After a 6-week washout period,
opposite tx given. Method of
randomization not given

"Young Mania Rating Scale ("manic)."
Point Subtraction Aggression Paradigm
("aggressive). "Verbal hostility subscale
score on Aggression Questionnaire of
Buss and Perry. "Phobic anxiety on
Symptom Checklist 90-R. No effect on
Hamilton Depression Rating Scale
(HAM-D)

4

Daly et al, 2001[109]

20 healthy men aged 18–42 years.

PO placebo daily for 3 days, then PO
methyltestosterone 40 mg/day for 3
days, then PO methyltestosterone 240
mg/day for 3 days, then PO placebo for 3
days inpatient. Schedule fixed but
unknown to subjects and raters (not clear
who the raters were inasmuch as
subjects self-rated).

High-dose methyltestosterone
associated with visual analogue scale
(VAS) self-rating of "Cognitive ability,
"Distractibility, "Energy, "Sexual
arousal, "Aggression, "Irritability.

2

3

(Continued)
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Table 4. (Continued)
O’Connor et al, 2002
[117]

30 healthy eugonadal men aged 23–
40 years; 8 hypogonadal men
included but given only active tx and
so not summarized here. One subject
dropped out; it is not clear if he was
retained in the analysis.

Testosterone enanthate 200 mg IM or
placebo weekly for 8 weeks (n = 15/
group). Method of randomization not
given

Dabbs et al, 2002[110] 16 healthy men and 17 women, mean Micronized T 40 mg or placebo gel
age 20.2 years (women are not
applied to the skin daily for 5 days
further discussed); 5 subjects (sex
not indicated) failed screening; 15
men were scored.

The authors reported a lack of effect of
testosterone on mood and aggression in
eugonadal men, but the analyses shown
in the paper were chiefly between
hypogonadal men and eugonadal men.

2

No difference in personality scores on
Gough and Heilbrun Adjective Check
List; some differences identified by study
authors on post-hoc analysis. "Hostility
on evaluation by 2 undergraduate judges
of a free-text paragraph written by each
subject on his mood at the end of tx

3

Kunelius et al, 2002
[118]

120 men, age 50–70 years, with
“andropause” symptoms, serum T
<15 nM (432 ng/dL). Six subjects
dropped out; it is not clear whether
they were included in the analysis.

No effect on well-being or mood as
“Randomized” by sealed envelope to
assessed by questionnaire.
2.5% DHT gel (125 mg/day DHT) or
placebo (60 subjects per group) for 30
days after which dose was adjusted on
serum DHT concentration to 187.5 or 250
mg/day DHT. Placebo dose was
randomly adjusted. Tx duration was 6
months.

5

O’Connor et al, 2004
[67]

28 healthy eugonadal men 22–44
years old; 4 subjects withdrew on tx
and were excluded.

T undecanoate 1000 mg or placebo IM at
the beginning of an 8-week tx phase
followed by 8-week washout followed by
the opposite tx. Self-assessment each
week and psychometric assessments
during week 4 of each tx phase

"Anger-hostility (during first 2 weeks after 3
injection) and #fatigue-inertia scores on
POMS. No effect on Aggression
Questionnaire, Partner Aggression
Questionnaire, or Aggression
Provocation Questionnaire, Buss Durkee
Hostility Inventory (irritability subscale),
Rathus Assertiveness Schedule, or State
Self-Esteem Scale

Howell et al, 2001[24]

35 men mean age 40.9 with some
degree of testicular dysfunction after
cytotoxic cancer therapy; blood LH
8 mIU/L and T <20 nM (576 ng/dL);
2 dropouts were excluded from
analysis.

T 2.5 or 5.0 mg patch (n = 16) or placebo
patch (n = 19) daily for 12 months;
randomization method not described,
study described as single-blinded

No effect on Hospital Anxiety and
Depression Scale (HADS).

3

Pugh et al, 2004[20]

20 men 44–81 years old with
impaired LV EF (mean 35%)

T 100 mg or placebo IM every 2 weeks
for 12 weeks. Subjects said to be
randomized, but randomization method
and the number of subjects per group
were not described.

BDI not affected; improvement identified
by authors was not statistically
significant.

3

Haren et al, 2005[119]

76 men 60–86 years old, mean age
68.5 years, with at least 2 symptoms
on ADAM and total T >8 nM (231 ng/
dL); 6 dropouts analyzed by ITT

T undecanoate 160 mg/day (n = 39) or
More GDS improvement in placebo vs T
placebo (n = 37) by mouth for 12 months; group
dose halved if hematocrit increased
above 50%; randomization in blocks of 4
using ADLS

5

Malkin et al, 2006[23]

76 men with CHF, mean age 64
years; 34 dropouts were retained for
analysis using ITT.

T 5 mg (n = 37) or placebo (n = 39) patch
daily for 12 months; randomization was
stratified by ischemic vs non-ischemic
heart failure. Method of randomization
not given

No effect on BDI

3

Brockenbrough et al,
2006[38]

40 hemodialysis patients with serum
T concentration <400 ng/dL (13.9
nM); 22 subjects completed the
study. Analyzed by ITT

Topical T 100 mg (n = 19) or placebo gel
(n = 21) daily for 6 months; block
randomized in groups of 4

Not possible to evaluate; Likert scale for 5
mood combined with scales for sexual
desire and reported as a composite score
not affected by tx
(Continued)
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Table 4. (Continued)
Okun et al, 2006[85]

Men with Parkinson disease and free
T concentration <100 pg/mL (347
pM), mean age 68 years

T enanthate 200 mg (n = 15) or placebo
(n = 15) IM every 2 weeks for 8 weeks;
dose could be adjusted upwards based
on free T concentration measured every
2 weeks; method of randomization not
given

No effect on GDS, State-Trait Anxiety
Inventory (STAI), or Visual Analog Mood
Scale (VAMS)

4

Knapp et al, 2008[41]

61 HIV-positive men, mean age 43
years, with involuntary weight loss
and/or BMI <20 mg/m2; 4 placeboassigned and 9 T-assigned subjects
dropped out and were analyzed using
the last observation carried forward.

T enanthate 300 mg (n = 31) or placebo
(n = 30) weekly for 16 weeks;
randomized by computer-generated list
in blocks of 6

"Mental health subscale of QoL
instrument. #Stress, anxiety, and
depression subscale scores

5

Maki et al, 2007[120]

15 men age 66–86 years, total blood
T >240 ng/dL (8.3 nM)

T enanthate 200 mg (n = 9) or placebo
(n = 6) IM every other week for 90 days
followed by 90-day washout followed by
the opposite tx; tx order determined by
coin toss

No tx effect on Positive and Negative
Affectivity Schedule

5

Vaughan et al, 2007
[112]

69 men 65–83 years (mean 70.8
years) with 2 morning serum T
concentrations <12.1 nM (350 ng/dL);
23 dropouts were excluded from
analysis.

T enanthate 200 mg IM every 2 weeks
+ placebo pill (n = 23), T enanthate 200
mg IM every 2 weeks + finasteride 5 mg/
day (n = 22), or placebo injection and
placebo pill (n = 23), tx for 36 months;
block-randomization by computer;
possible reduction in T dose if hematocrit
>52%; cognitive tests at baseline, 4, and
36 months

#Scores in Speilberger Test of Anxiety.
No effect on BDI

5

Zak et al, 2009[122]

25 male students, mean 20.8 years
old.

T 1% gel 10 g or placebo given prior to
playing game; each man served as his
own control. Randomization of tx order
not discussed

"Selfishness in game designed to test
selfishness

4

Giltay et al, 2010[75]

184 men age 35–69 (mean 52.1) with
T concentration <12.0 nM (346 ng/dL)
or calculated free T concentration
<225 pM (6.5 ng/dL) who had
metabolic syndrome; 14 dropouts (8
T, 6 placebo) analyzed with last
observation carried forward

T undecanoate 1000 mg (n = 113) or
placebo (n = 71) IM given at week 0, 6,
18, and 24; evaluations at week 30.
Randomization method not given except
to say that T was over-assigned in a 7:3
ratio

"Improvement in BDI

4

Borst et al, 2014[102]

Men aged 60 or more with total T
300 ng/dL (10.4 nM) or bioavailable
T 70 ng/dL (2.4 nM)

T enanthate 125 (n = 14) or 0 (n = 16)
mg/week IM for 23 months. There also
were finasteride + T arms that we ignore
here.

T-associated reduction of a mean of 0.74
items on the 15-item Geriatric
Depression Scale short form

1

Mirdamadi et al, 2014
[22]

50 males, age 50–70, with CHF

T enanthate 250 mg IM or saline placebo
IM every 4 weeks for 12 weeks

No difference between groups in BDI

3

Subjects were block randomized to
receive testosterone undecanoate 1000
(n = 97) or 0 (n = 102) mg IM at week 0,
6, and 18.

No improvement in Hospital Anxiety and
Depression score (HADS) in men with
baseline T 8.0 nM; "HADS-depression
score but not HADS-anxiety in men with
baseline T 8.1–12 nM

5

100 mg T or placebo IM every 2 weeks
for 4 weeks, 1 month washout, then tx
switch; randomization by computer;
single-blinded

#BDI score

5

Hackett et al, 2014[58] 199 men aged 18–80 with T2DM with
total T between 8.1–12 nM (233–346
ng/dL) or total T 8.0 nM (231 ng/
mL). 9 patients did not complete the
study; 4 because of serious adverse
events (3 treatment unrelated deaths,
1 prostate cancer in placebo), and 5
withdrew their consent.
Malkin et al, 2004[1]

12 men 60.8 ± 4.6 years old
(mean ± SD) with CAD and “clinical
need for T replacement.” One man
failed screening and another
withdrew at unspecified point in the
study.

(Continued)
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Table 4. (Continued)
MEN WITH PSYCHIATRIC DISORDERS
HIV-Positive
Grinspoon et al, 2000
[129]

52 men, mean age 41.6, with AIDST 300 mg (n = 21) or placebo (n = 18) IM
associated wasting (weight <90% of
every 3 weeks for 6 months.
ideal or weight loss >10%) and serum
free T concentration <12 pg/mL (416
pM); 21 of these men had baseline
BDI >18; 13 subjects died or withdrew
and were not evaluated.

Improved BDI by a mean of 5.8 points;
improvement was associated with
increased weight. BDI did not change
with placebo. Men with BDI >18 at
baseline were not analyzed separately.

Rabkin et al, 2000[35]

72 HIV-positive men, mean age 39,
with serum T <17.4 nM (501 ng/dL)
with sexual dysfunction and at least
one “hypogonadal” mood symptom; 2
dropped out and were excluded from
analysis. Among 70 remaining, 26
had MDD, dysthymia, “minor”
depression, or MDD in remission.

Randomization in blocks of 4 by
computer-generated numbers to T
cypionate (n = 38 overall, 26 with
depression diagnosis) or placebo (n = 32
overall, 7 with a depression diagnosis)
injected biweekly (presumably IM) for 6
weeks; the first T dose was 200 mg,
subsequent doses were 400 mg. Openlabel phase with T followed the 6-week
double-blind study, not summarized here

4
Clinical Global Impression (CGI) scale
response (not defined) in 74% T and 19%
placebo (P < 0.001). No effect of tx on
CGI in subjects with a depression
diagnosis (P = .08). Improvement in total
and vegetative scores on HAM-D, but not
the affective scale. No change in the BDI
(P = .052)

Rabkin et al, 2004
[130]

123 HIV-positive men, mean age 41,
with MDD or dysthymia; 33 men
dropped out and were retained for
ITT analysis.

Randomization in blocks of 6 by
computer-generated numbers to T
cypionate IM biweekly + daily PO
placebo (n = 38), placebo IM biweekly
+ fluoxetine PO (20–40 mg) daily
(n = 46), or placebo IM biweekly
+ placebo PO daily (n = 39). Initial T dose
was 200 mg, subsequent doses were
400 mg. Within tx groups, subjects were
also randomized to fluoxetine or placebo
daily by mouth. Tx were given for 8
weeks. Eight of the subjects were
randomized only to fluoxetine or placebo
due to transient unavailability of T.

No difference in response on HAM-D or
BDI by ITT and by considering only
completers. Improvement in Chalder
Fatigue Scale compared to placebo and
to fluoxetine

4

Reddy et al, 2000[121] 22 men 65 years old; 8 dropouts at
different times were analyzed only for
those forms they completed.

T enanthate 200 mg (n = 14) or placebo
(n = 8) IM every 2 weeks for a total of 4
doses.

No effect on Short-Form 36 (SF-36) or
Psychological General Well-Being

3

Seidman et al, 2001
[36]Seidman &
Roose, 2006.[164]

32 men 33–71 years old with MDD
(DSM-IV criteria) and serum T 350
ng/dL (12.1 nM); 2 dropouts were
excluded from analysis.

T enanthate 200 mg (n = 13) or placebo
(n = 17) IM weekly for 6 weeks

Improved QoL score. HAM-D and BDI
4,
described as improved in both groups; no 4
intergroup difference. No difference
between groups in response rate,
defined as a 50% decrease in the
HAM-D or as defined by CGI

Pope et al, 2003[125]

23 men with tx-refractory MDD
(DSM-IV criteria) and serum T 350
ng/dL (12.1 nM); 22 randomized (1
man who responded to run-in placebo
gel excluded)

T gel 1% (n = 12) or placebo gel (n = 10)
for 8 weeks; valid randomization
procedure described. T dose reduced if
serum T exceeded 1070 ng/dL; sham
reductions performed in placebo gel.
Usual antidepressants continued during
trial

"Rate of decrease in HAM-D and CGI
scores; no difference in rate of change in
BDI "Response as evaluated by HAM-D
but no significant change in CGI or BDI

5

Kenny et al, 2004[124] 11 men with MMSE scores of 14–28,
cognitive impairment by Dementia
Rating Scale, and serum free T <128
ng/dL (4.44 nM); none discontinued.

T enanthate 300 mg (n = 6) or placebo
(n = 5) IM every 3 weeks for 9 weeks;
testing at 10 weeks. Method of
randomization not given.

No effects on behavior with Behave AD
or mood with GDS

3

Cavallini et al, 2004
[48]

T undecanoate 160 mg/day (n = 40),
carnitine (n = 45, not further considered
here), or placebo (n = 45) taken PO for 6
months; randomization by color-coded
boxes

HAM-D improved at 3 but not at 6 months 4

3

HIV-Negative

150 men 60–74 years old with
symptoms of androgen decline,
including decreased libido and
erectile quality, depressed mood and
concentration, irritability, and fatigue;
free T <6 pg/mL (21 pM); 20 dropouts
excluded

(Continued)
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Table 4. (Continued)
Seidman et al, 2005
[127]

26 men, mean age 46.4 years, with
MDD partially or nonresponsive to 2
adequate antidepressant trials

T group (n = 13) received IM T enanthate No difference between groups in
200 mg/week IM × 2 weeks, then 400
improvement by HAM-D or BDI
mg, then 400 mg (if responsive) or 600
mg (if not responsive) for the final
injection; placebo group (n = 13) received
weekly IM saline for 4 weeks. Tx
allocation by random number table.
Antidepressants continued. Evaluation at
6 weeks

5

Orengo et al, 2005
[128]

18 men >50 years old with residual
depression (12 on HAM-D) in spite
of at least 6 weeks of antidepressant
therapy and serum T 350 ng/dL
(12.1 nM); 6 men dropped out and
were not included in the analysis.

Random number generator used to
randomize men to T 1% gel 5 g/day or
placebo gel for 12 weeks followed by
crossover to the other tx; 5 subjects
received placebo first and 7 subjects
received T first. Evaluations every 6
weeks

Improvement in HAM-D scores after 12
weeks of T compared to baseline, but no
difference between T and placebo. No
effect of tx on QoL Satisfaction
Questionnaire or POMS

3

Lu et al, 2006[42]

18 men with AD; 2 dropouts were
excluded from analysis; last
observation carried forward for ITT
analysis was reported not to change
the results.

T gel 75 mg/day (n = 9) or placebo gel
(n = 9) for 24 weeks

No tx effect on Neuropsychiatric
Inventory, BDI, or self-assessed
QoL-AD. Improvement in caregiverassessed QoL-AD

3

Ko et al, 2008[123]

30 schizophrenic men, 20–49 years
old, on antipsychotic medication; 4 of
these subjects withdrew and were
retained for ITT analysis.

T 1% gel 5 g (n = 15) or placebo (n = 15)
applied daily for 4 weeks; method of tx
assignment not discussed

Improvement in the negative symptom
3
scores on the Positive and Negative
Syndrome Scale. No change in the
Calgary Depression Scale for
Schizophrenia; the authors implied better
results for completers, but there was still
no significant difference from placebo.

Seidman et al, 2009
[51]

23 men, mean age 50.6 years, with
T cypionate 200 mg (n = 13) or placebo
dysthymia and serum T concentration (n = 10) IM every 10 days for 6 weeks;
<350 ng/dL (12.1 nM).
randomization by computer

Shores et al, 2009
[126]

Greater improvement in HAM-D and BDI
than with placebo. "Remission (CGI of 1
or 2 or HAM-D < 8) for 7 men on T
(n = 13) compared to 1 man on placebo
(n = 10).

5

33 men 50 years old (mean age 59
years) with dysthymia or “minor
depression” and T concentration
280 ng/dL (9.7 nM); 6 subjects
discontinued and were included in
ITT analysis.

T gel 7.5 g (n = 17) or placebo (n = 16) for Greater improvement in HAM-D than
12 weeks; “randomization” by computer
placebo. "Remission (HAM-D 7): 9/17
using 1:1 ratio
men in T group vs. 3/16 men in placebo
group. No effect on Hopkins Symptom
Checklist, SF-36, or QoL Enjoyment and
Satisfaction Questionnaire.

5

Pope et al, 2010[111]

100 men, 30–65 years old, with MDD
with partial or no response to
antidepressant therapy and serum T
350 ng/dL (12.1 nM); 81 men
completed at least 4 weeks of tx, 74
men completed the study. ITT
analysis used for 95 subjects who
had at least 1 post-baseline
evaluation.

T gel 5 g/day or placebo for up to 6
weeks (n = 50/group); the dose could be
altered based on serum T concentration.
“Randomization” by sealed envelope

No effect on HAM-D, CGI, or
Montgomery Asberg Depression Rating
Scale (MADRS)

5

Amiaz et al, 2011[37]

100 depressed men 30–65 years old
with MDD (DSM-IV criteria), with a
HAM-D score 12 in spite of
currently taking a serotonergic
antidepressant for at least 4 weeks,
serum testosterone 350 ng/dL (12.1
nM); 37 subjects were not evaluable
due to loss of data and withdrawal.

T (n = 31) or placebo (n = 32) gel for 6
weeks; allocation using table of random
numbers blocked at 50/group; tx period
varied from 15 days to 6 weeks.

Improvement in HAM-D and MADRS

5

doi:10.1371/journal.pone.0162480.t004
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amounts of money.[122] Two additional studies from the same group in non-depressed men
with CHF did not show an effect of testosterone on the Beck Depression Inventory (BDI),[20,
27] although the earlier of these studies concluded otherwise based on a finding that was not
statistically significant. A study in non-depressed men with metabolic syndrome reported an
improvement in the BDI in testosterone-treated compared to placebo-treated subjects.[52] A
study found non-depressed men older than 60 years to have a mean 5% decrease in a geriatric
depression scale when administered testosterone.[102] This study had a Jadad score of 1.
Another study [58] found that testosterone treatment had no effect on the Hospital Anxiety
Depression score (HADS) in men with testosterone 8.0 nM but improved the depression subset of the HADS in men with testosterone of 8.1–12 nM. Malkin et al.[1] found that 100 mg testosterone every 2 weeks improved the BDI score. This study had a Jadad score of 5.
3.4.2 Men with psychiatric diagnoses. Twelve studies (3 in HIV-positive men) evaluated
testosterone supplementation in men with a diagnosis of depression or dysthymia (sometimes
also called, “minor depression”), 1 study evaluated the use of testosterone in men with schizophrenia, and 2 studies were conducted in men with Alzheimer disease or cognitive impairment.
The study in schizophrenic men used testosterone or placebo gel in addition to whatever treatment the subject was already using.[123] There were improvements in the negative symptom
scores on a standardized scale but no change in the Calgary Depression Scale for Schizophrenia. The authors used an intention-to-treat (ITT) analysis and implied that better results were
seen among subjects who completed the study; however, there were no significant differences
in the depression scores between testosterone and placebo among completers. Two studies in
men with cognitive impairment or Alzheimer disease (Jadad score 3) found no effect of treatment on neuropsychiatric symptoms, depression, behavior, or quality of life (QoL).[42, 124]
Caregiver-assessed QoL was improved in 1 of these studies.[42]
The response of depression and dysthymia to testosterone was mixed and inconsistent.
Among HIV-negative men, four studies (all with a Jadad score of 4 or 5) showed testosteroneassociated improvements in standard scoring systems for depression and/or in the proportion
of subjects who achieved remission of their psychiatric disorder.[37, 51, 125, 126] Four other
studies (2 with a Jadad score of 4 or 5) showed no improvement in depression or dysthymia
with testosterone compared to placebo.[36, 111, 127, 128] One study (Jadad score 4) showed a
transient improvement in depression and melancholia after 3 months of treatment that was no
longer apparent after 6 months of treatment.[48]
Because it has been noted that HIV-positive men can be depressed and “hypogonadal,” 3
studies administered testosterone to HIV-positive men with depression or dysthymia.[35, 129,
130] Two of the studies had a Jadad score of 4[35, 130] and one study had a Jadad score of 3.
[129] Testosterone treatment had inconsistent effects on measures of depression; one study
showed a 5.8-point improvement in the Beck Depression Inventory (BDI) in men with HIVassociated wasting, although the improvement may have been explained by an increase in
weight.[129] Another study showed a testosterone-associated improvement in HIV-positive
men overall in the Clinical Global Impression (CGI) scale but not among subjects with a
depression diagnosis.[35] This study also showed improvement in the total and vegetative
symptom scores of the Hamilton Rating Scale for Depression (HAM-D) but not in the affective
scale, and there was no significant change in BDI scores. A subsequent, larger study by the
same group showed no difference in response of depression measured by HAM-D or BDI in
men given testosterone compared to placebo.[130]
Authors attributed the mixed responses in the literature to the considerable placebo
response in most studies and to the possibility of an idiosyncratic response to testosterone,
with putative subgroups of responders who were difficult to identify a priori.[111, 127] The
studies, however, did not show consistent responses in subgroups of men who had low serum
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testosterone concentrations, depression resistant to standard therapy, or men characterized as
middle-aged or elderly. In studies in which serum testosterone concentrations were measured
on therapy (both with a Jadad score of 5), response of depression or dysthymia was not consistently associated with serum hormone concentration.

3.5 Cognition
Twenty-two studies evaluating the effects of testosterone on cognition are summarized in
Table 5. Seventeen focused on men without cognitive impairment and 4 focused on men with
cognitive impairment.
3.5.1 Men described as normal. Ten studies evaluated the effects of testosterone treatment
on cognitive endpoints in healthy men. Spatial cognition/memory was reported to be improved
with testosterone supplementation in 3 studies,[114, 131, 132] unchanged in 2 studies,[42, 133]
and poorer with supplementation in 1 study.[134] Although 1 study reported improved working
memory[135] and 1 study found improved verbal fluency,[134] most other studies found no
improvement in verbal fluency, memory, or other cognitive endpoints in healthy men given testosterone.[42, 91, 120, 131, 133, 134, 136] Two of 5 studies that showed improvement and 4 of 7
of the studies that showed no improvement had a Jadad score of 4 or 5.
3.5.2 men described as hypogonadal. Hypogonadal men, variously defined, were found
in 1 study to have better verbal learning and reversal of digits on number sequencing with testosterone supplementation,[112] but no effect on the same domain was found in another
study.[137] The study showing an advantage used injected testosterone enanthate 200 mg
while the negative study used a daily 5 mg patch. Another injection study found no effect of
supplementation on memory in hypogonadal men.[104] One study reported a possible disadvantage of treatment with dihydrotestosterone compared to placebo in performance on the
Modified Mini-Mental State Examination (MMSE),[11] but data were not shown and the putative difference could not be evaluated. Another study showed no improvement in visuospatial
cognition or MMSE with testosterone treatment for 12 months.[119] All studies had Jadad
scores of 4 or 5.
3.5.3 Men with cognitive impairment. Treatment of men with suspected or diagnosed
Alzheimer disease or cognitive impairment was reported in five studies, two of which had a
Jadad score above 3. Although 1 injection study found an improvement on the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-COG),[138] another study using testosterone gel found no effect on the same instrument or on other cognitive function tests.[42] Spatial
and verbal memory were improved after 6 weekly injections of testosterone enanthate in 1
study, but the effect did not persist during a 6-week washout period without treatment.[132] A
fourth study found no effect of testosterone injections on behavior, activities of daily living
(ADLs), or cognition.[124] The fifth study found that transdermal testosterone gel was not
associated with statistically significant changes in measures of cognition, mood, or quality of
life.[139]
3.5.4 Proposed explanations for inconsistent results. Because study results have been
varied and inconsistent, some authors have proposed that testosterone is not the only factor or
even the most important factor in cognitive function. Janowsky et al[114] found improved spatial cognition in men treated with scrotal testosterone patches, but there was an imbalance
between placebo and testosterone groups in baseline blood concentrations of 17β-estradiol,
which these authors attributed to chance. The effect of testosterone and 17β-estradiol on spatial
cognition testing was explored using post-hoc testing, and the putative testosterone effect on
spatial cognition appeared to be associated with suppression of 17β-estradiol by testosterone
supplementation rather than a direct effect of testosterone. This study had a Jadad score of 3.
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Table 5. Effects of Testosterone on Cognition.
MEN WITHOUT COGNITIVE IMPAIRMENT
Janowsky et al,
1994[114]

56 healthy men 60–75 years old

15 mg T scrotal (n = 27) or placebo patch
(n = 29) 16 hours daily for 3 months;
method of randomization not discussed

No effect on verbal memory (California
Verbal Learning Test), visual memory
(Visual Reproduction subtest of the
Wechsler Memory Scale), manual
dexterity (Grooved Pegboard Test),
cognitive flexibility (Trail-Making Test
[TMT]). Improved spatial cognition
(revised block design subtest of Wechsler
Adult Intelligence Scale [WAIS]),
attributed to decreased estradiol

3

Dobs et al, 1999 133 men with AIDS age 18–65+ who had
[113]
lost 5–20% of baseline weight with a
morning serum total T 400 ng/dL (13.9
nM) or free T 16 pg/mL (56 pM); 15 T
and 20 placebo did not complete the
study.

15 mg T (n = 67) or placebo (n = 66) patch No effect on cognitive assessed by Rand
applied 20–24 hours/day to shaved scrotal HIV, SF-36, or EUROQoL Feeling
skin for 12 weeks; assessments at weeks Thermometer
4, 8, and 12; randomization method not
given

3

Janowsky et al,
2000[135]

19 men 61–75 years old.

T enanthate 150 mg (n = 10) placebo
(n = 9) given IM each week for 1 month;
randomization method not given

Improved working memory (Subject
Ordered Pointing Test)

2

Wolf et al, 2000
[133]

30 men, mean age 68 years.

T enanthate 250 mg (n = 17) or placebo
(n = 13) given IM one time; testing
occurred 5 days after injection; method of
randomization not given

Poorer performance on verbal fluency
test. No tx effect on spatial or verbal
memory (immediate or delayed recall),
Stroop test, or mental rotation

2

O’Connor et al,
2001[134]

20 men age 19–45 years (mean age 28.2
years)

T enanthate 200 mg (n = 15) or placebo
(n = 15) IM weekly for 8 weeks; testing at
4 and 8 weeks

Improved verbal fluency (Controlled Oral
Word Association Test). Poorer
performance on revised block design
subtest of the WAIS. No tx effect on
cognitive flexibility (TMT), revised
vocabulary subtest of the WAIS,
visuomotor dexterity and speed (Grooved
Pegboard test), or Rey Auditory Verbal
Learning Test (RAVLT)

2

Cherrier et al,
2001[131] and
2004[170]

28 healthy men age 50–80 (mean age 67
years); 3 dropouts were excluded from
analysis after randomization.

T enanthate 100 mg (n = 15) or placebo
(n = 13) IM every week for 6 weeks
followed by 6-week washout. Testing at
weeks 0, 3, 6, and 12. Method of
randomization not given

Improvement in some, but not all, tests of
spatial memory. No effect on attention or
verbal fluency; Story-recall ability
associated with T and estradiol serum
concentrations. Week 12 (washout)
results not shown

5,
5

Cherrier et al,
2005[136]

60 men age 50–85 years (mean age 65
years); 3 dropouts after randomization
excluded from analysis.

T enanthate 100 mg IM each week + daily
placebo pill (n = 20) or T enanthate 100
mg IM each week + anastrozole 1 mg PO
daily (n = 19); IM or placebo injection
every week for 6 weeks + daily placebo pill
(n = 21) followed by 6-week washout.
Testing at weeks 0, 3, 6, and 12. Method
of randomization not given

Improvement in spatial memory with T tx
only at the washout visit. Improvement in
spatial memory with T + anastrozole at 6
weeks and at the washout visit.
Improvement in verbal recall with T tx, not
persisting to washout visit. No effects on
verbal fluency, attention, or working
memory

5

Lu et al, 2006
[42]

29 healthy men; 7 dropouts were
excluded from analysis; last observation
carried forward for ITT analysis was
reported not to change the results.

T gel 75 mg/day (n = 14) or placebo gel
(n = 15) for 24 weeks; method of
randomization not given

No tx effect on Alzheimer Disease
Assessment Scale-Cognitive Subscale
(ADAS-COG), California Verbal Learning
Test, revised block design subtest of the
WAIS, Judgment of Line Orientation, or
Developmental Test of Visual-Motor
Integration

3

(Continued)
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Table 5. (Continued)
Maki et al, 2007
[120]

15 men age 66–86 years, total blood T
>240 ng/dL (8.3 nM)

T enanthate 200 mg (n = 9) or placebo
(n = 6) IM every other week for 90 days
followed by 90-day washout followed by tx
switch; tx order determined by coin toss

Poorer performance in verbal memory
5
(California Verbal Learning Test). No tx
effect on short-term memory for geometric
figures (Benton Visual Retention Test),
attention and working memory (Digit
Span), working memory and attention (αSpan), manual dexterity (Grooved
Pegboard), attention, visuomotor
scanning, and cognitive flexibility (TMT)

Cherrier et al,
2007[140]

57 healthy men age 50–90 years (mean
age 67 years).

T enanthate 50, 100, or 300 mg or placebo
IM weekly for 6 weeks followed by 6-week
washout. Testing at weeks 0, 3, 6, and 12.
Randomized using random number
generator. Number of subjects in each
group not given

Performance by assigned dose group not
given. Improved verbal and spatial
memory in men whose serum T increased
11–50 nM (318–1446 ng/dL) above
baseline (3 men received 50 mg T
enanthate, 17 men received 100 mg, and
2 men received 400 mg)

Emmelot-Vonk
et al, 2008[91]

237 healthy men 60–80 years old with
T < median; ie, <13.7 nM (395 ng/dL); 30
dropouts, 16 of whom provided some
follow-up information

T undecanoate 160 mg (n = 120) or
placebo (n = 117) by mouth daily for 6
months; randomization by computergenerated list using blocks of 6

No effect on cognitive function (Benton
5
Judgment of Line Orientation, Digit symbol
substitution, Shepard Mental Rotation,
RAVLT, TMT)

Sih et al, 1997
[104]

32 men age 51–79 with free blood T <60
ng/dL (2.1 nM); unclear how dropouts
after randomization were handled

T cypionate 200 mg (n = 10) or placebo
(n = 12) every 14–17 days for 12 months;
tx allocation by random number (not
otherwise characterized)

No effect on memory (RAVLT+ recall; Rey
Visual Design Learning Test + recall;
Animal Naming)

4

Ly et al, 2001
[11]

37 men mean age 68.2 years with plasma
T 15 nM (432 ng/dL); 4 dropouts were
excluded from analysis.

DHT gel 70 mg (n = 18) or placebo
(n = 19) applied daily for 3 months;
method of randomization not discussed

No effect or possible worsening of MMSE
(placebo group had a “minor increase in
total score and 3-word recall that was not
evidence in DHT-treated participants.”
Data were not shown.

5

Kenny et al,
2002[137]

67 men age 65–87 years (mean 76 years) T 5 mg/d (n = 24) or placebo patch
with free T <128 ng/L (4.44 nM); 23
(n = 20)
dropouts appear excluded from analysis

Haren et al,
2005[119]

76 men 60–86 years old, mean age 68.5,
with at least 2 symptoms on the ADAM
questionnaire and total T >8 nM (231 ng/
dL); 6 dropouts analyzed by ITT

Okun et al,
2006[85]

Men with Parkinson disease and free T
T enanthate 200 mg (n = 15) or placebo
<100 pg/mL (347 pM), mean age 68 years (n = 15) IM every 2 weeks for 8 weeks;
dose could be adjusted upwards based on
free T concentration measured every 2
weeks; method of randomization not given

Improved scores on Hopkins Verbal
Learning Test and backward visual span.
No effect on Controlled Oral Word
Association, revised block design subtest
of the WAIS, Mental Rotations Test, digit
span, visual span, Subject Ordered
Pointing Task, TMT, or Stroop test

4

Vaughan et al,
2007[112]

69 men age 65–83 (mean 70.8) with 2
morning serum T concentrations <12.1
nM (350 ng/dL); 23 dropouts excluded
from analysis

Better reversal of digits on forward and
backward number sequencing (Digit
Span). Better performance on verbal
learning (Selective Reminding test). No tx
effect on attention (TMT A), executive
functioning (TMT B), visuospatial skills
(Judgment of Line Orientation), visual
memory (Benton Visual Retention test)

5

Tan & Pu, 2003
[138]

10 men age 68–80 (mean 72.4) with a
new diagnosis of AD with total T <240 ng/
dL (8.3 nM); management of dropouts not
discussed

Improved performance on ADAS-COG
and MMSE.

2

No tx effect on Digit Span, Digit Symbol, or 4
TMT

T undecanoate 160 mg/day (n = 39) or
No effect on TMT B, visuospatial block
placebo (n = 37) by mouth for 12 months; test, or MMSE
dose halved if hematocrit increased above
50%; randomization in blocks of 4 using
ADLS

T enanthate 200 mg IM every 2 weeks
+ placebo pill (n = 23), T enanthate 200
mg IM every 2 weeks + finasteride 5 mg/
day (n = 22), or placebo injection and pill
(n = 23), tx for 36 months; blockrandomization by computer; possible
reduction in T dose if hematocrit >52%;
cognitive tests at baseline, 4, and 36
months

5

5

MEN WITH COGNITIVE IMPAIRMENT
T enanthate 200 mg (n = 5) or placebo
(n = 5) IM every two weeks for 12 months;
randomization method not given. Testing
every 3 months; statistical methods not
given

(Continued)
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Table 5. (Continued)
Kenny et al,
2004[124]

11 men age 73–87 with MMSE scores of
14–28, cognitive impairment by Dementia
Rating Scale, and serum free T <128 ng/
dL (4.44 nM); no subject discontinued

T enanthate 300 mg (n = 6) or placebo
(n = 5) IM every 3 weeks for 9 weeks;
testing at 10 weeks. Method of
randomization not given

No effects on behavior (Behave AD),
activities of daily living (Katz ADL), and
cognition (Digit Span, Clock face, verbal
fluency, TMT B)

3

Cherrier et al,
2005[132]

32 men, 63–85 years old, diagnosed with T enanthate 100 mg (n = 19) or placebo
Improved spatial and verbal memory did
probable AD or mild cognitive impairment; (n = 13) IM weekly for 6 weeks followed by not persist during washout period. No
4 dropouts excluded from analysis
6-week washout. Testing at 3, 6, and 12
effect on verbal fluency or attention
weeks. Randomization by random number
generator

5

Lu et al, 2006
[42]

18 men with AD; 2 dropouts excluded
from analysis; last observation carried
forward for ITT analysis reported not to
change results

T 75 mg/day (n = 9) or placebo gel (n = 9)
for 24 weeks

Cherrier et al,
2015[139]

22 men age 60–90 with mild cognitive
impairment and total T concentration
<300 ng/dL (10.4 nM) and AUA symptom
score <19

Transdermal testosterone gel 50 to 100
No significant changes in measures of
mg/day, with a target total T level of 500 to cognition, mood, or quality of life
900 ng/dL (n = 10) or placebo gel (n = 12)
X 6 months

No tx effect on ADAS-COG, California
3
Verbal Learning Test, revised block
design subtest of the WAIS, Judgment of
Line Orientation, or Developmental Test of
Visual-Motor Integration
5

doi:10.1371/journal.pone.0162480.t005

Most authors with an interest in 17β-estradiol have suggested that the effectiveness of testosterone, when it has shown effectiveness, is due to aromatization to 17β-estradiol. Cherrier
et al[131] measured testosterone and 17β-estradiol concentrations after injection of testosterone supplements in healthy men and reported that both testosterone and 17β-estradiol concentrations were associated with recall of a test story, but only 17β-estradiol concentrations were
associated with performance on the Stroop test. In another study, Cherrier et al reported that
only men with an increase in 17β-estradiol concentration after testosterone supplementation
showed improvements in verbal memory testing.[136] This study used administration of the
aromatase inhibitor anastrozole to differentiate between effects attributable to testosterone and
those that might be due to 17β-estradiol. Another study without anastrozole found 17β-estradiol serum concentrations after testosterone therapy to be a significant predictor of performance on verbal memory testing.[140] All three studies had a Jadad score of 5.
It has also been suggested that testosterone supplementation has produced inconsistent results
in cognitive function studies because the blood concentrations achieved by supplementation
need to be in an optimum range for effectiveness. Under this hypothesis, over-supplementation
is as ineffective as under-supplementation. Cherrier et al[140] administered testosterone
enanthate IM at 0, 50, 100, or 300 mg weekly and administered tests of verbal and spatial memory. Results were not reported according to treatment group; rather, subjects were divided into
those with no, moderate, or large increases in serum testosterone concentrations over baseline.
These response categories were defined based on 1 standard deviation above the control response
and 1 standard deviation above the response to 100 mg. Subjects with a moderate increase in
serum testosterone concentration over baseline (defined as 11–50 nM) performed better on cognitive testing than those with “no increase” (0–10 nM) or a large increase (>51 nM). Seventeen
of the 22 men in this moderate-increase group had received testosterone 100 mg/week with the
balance evenly divided between the 50 mg and 300 mg doses. The authors explained that they
did not use tertiles or quartiles, because using quartiles or tertiles resulted in some placebo
patients with significant changes from baseline, raising the question of whether men on placebo
with an increase in their serum testosterone concentration were distinguishable on cognitive testing from men who received testosterone supplementation. This study had a Jadad score of 5.
In summary, there is no support for the use of testosterone to enhance cognition in normal
or cognitively impaired men.
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4. Discussion
This systematic review examined published RCTs of testosterone supplementation for cardiovascular disease or surrogates of cardiovascular disease, sexual function, muscle strength,
mood, and cognition. The review was limited to published studies in English and to trials
indexed before April 9, 2016. The evidence supporting the use of testosterone for preventing or
treating cardiovascular disease is inconsistent and, on balance, unconvincing. Some evidence
supported an acute and chronic effect of testosterone therapy on increasing time to ST-segment
depression, and there is evidence of improvement in some measures of congestive heart failure.
Most studies showed no effect of testosterone therapy on inflammatory markers, and the effects
on lipids were inconsistent.
Studies that examined clinical effects have not favored testosterone therapy over placebo.
Two of 3 studies that assessed angina showed no effect. Three studies from the same group
found a benefit for symptoms associated with CHF. One study was stopped early for cardiovascular adverse effects.
Testosterone supplementation did not demonstrate consistent effectiveness for improving
sexual function or satisfaction. Testosterone is ineffective in treating ED. Controlled trials were
mixed on libido, with more positive than negative studies.
Substantial evidence supports a favorable effect of testosterone treatment on muscle mass in
both healthy men and men with HIV, and a majority of studies showed a decrease in fat mass.
Testosterone did not affect most measures of muscle strength. While decreasing frailty and
increasing strength in older men might be beneficial, testosterone supplementation does not
improve physical function in older men.
Most studies on mood-related endpoints found no beneficial effect of testosterone treatment on personality, psychological well-being, or mood. Although 2 studies showed
decreased anxiety, treatment of depression showed mixed and inconsistent results. Even if
testosterone did benefit mood, social adverse events might ensue; 5 studies noted treatmentrelated increases in anger, aggression, or hostility. Testosterone did not benefit cognitive
impairment or Alzheimer disease; neither did it benefit verbal fluency, memory, or other cognitive endpoints in normal men.
In summary, evidence from RCTs does not support treatment of so-called low-T for
improving physical function, sexual function, mood, or cognition. Testosterone increases muscle mass, but not strength, and while some improvement is seen in some surrogate markers of
cardiovascular risk, there is little evidence of clinical benefit.
There is conflicting evidence on the association between testosterone supplementation and
cardiovascular events. RCTs have reported increased cardiovascular risk with testosterone
therapy. One such trial that specifically examined cardiovascular disease and mortality endpoints was stopped early because of an increased risk of cardiovascular events.[17] A metaanalysis of 2994 men in 27 randomized controlled trials through 2012 found that testosterone
therapy increased the risk of cardiovascular events (OR, 1.54; 95% CI, 1.09–2.18).[141]
Observational studies examining the effect of testosterone treatment have shown conflicting
results on risk. A Veterans Administration study evaluated men who had undergone coronary
angiography and had a total testosterone concentration (presumably plasma) less than 300 ng/
dL (10.4 nM).[142] Men who were treated with testosterone had an increased risk of all-cause
mortality, MI, and stroke compared to men who did not use testosterone (HR, 1.29; 95% CI,
1.05–1.58), based on a mean of 27.5 months of follow-up. Another retrospective cohort study
using Veterans Administration data showed a lower rate of all-cause mortality, myocardial
infarction, and stroke among testosterone-treated men whose testosterone concentrations
“normalized” after treatment.[143] Another observational study of men in a large, integrated
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health care organization found that death rates were reduced over 3 years, but there was no
effect on myocardial infarction or stroke.[144]
A Medicare-based study identified testosterone exposures and MI outcomes using claims
data and matched testosterone-treated with untreated subjects using an empirically derived
propensity score and found no increased risk.[145] The adjusted HR for testosterone therapy
and MI was 0.84 (95% CI 0.69–1.02). Analysis of subjects in the highest quartile propensity
score range suggested a protective effect of testosterone treatment, with a HR of 0.69 (95% CI
0.53–0.92). An observational study in men with low testosterone found that treatment was
associated with reduced mortality;[146] another in diabetics[147] reported benefit on all-cause
mortality but excluded men who had received testosterone for less than one year and excluded
deaths occurring before six months. A large cohort study found that myocardial infarction
rates were significantly increased within three months of testosterone treatment initiation; testosterone-treated men over 65 experienced double the rate of myocardial infarctions compared
to men who did not received testosterone.[148]
Testosterone treatment has been considered for disease prevention because men who are
obese, diabetic, hypertensive, or chronically ill have lower plasma concentrations of testosterone.[149] However, the direction of causality is unclear; it is possible that obesity or lack of
exercise and chronic disease lower testosterone rather than low testosterone concentrations
causing disease. It is also possible that another mechanism both lowers testosterone concentrations and increases the risk of some diseases. Observational studies attributing positive health
effects to testosterone may be affected by an increased likelihood of healthier men being prescribed testosterone rather than testosterone improving health.
There are parallels between the recommendation of testosterone and of menopausal hormone therapy in women. Physicians prescribed estrogen and estrogen-progestin preparations
to menopausal women to prevent cardiovascular disease because observational studies showed
that women who took menopausal hormones had less heart disease than women who did not.
RCTs, however, showed that menopausal hormone therapy increased the risk of heart attacks
and stroke.[150–153] It is likely that healthier women chose to take menopausal hormone therapy, but menopausal hormone administration did not improve health.
In 2012, sales for testosterone therapies exceeded $2 billion, and sales continue to grow in
dozens of countries.[154] To the extent that this increase in use of testosterone supplementation
is based on anticipated improvements in cardiovascular health, sexual function, physical functioning, mood, or cognition, we suggest that it might represent therapy without adequate clinical
trial support. We identified no population of normal men for whom the benefits of testosterone
use outweigh its risk. Given the known risks of testosterone therapy and the lack of evidence for
clinical benefits in normal men, we do not think further trials of testosterone are necessary.
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